



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 9/107	A2	(11) International Publication Number: WO 96/40055 (43) International Publication Date: 19 December 1996 (19.12.96)
(21) International Application Number: PCT/IB96/00799 (22) International Filing Date: 7 June 1996 (07.06.96) (30) Priority Data: 08/478,978 7 June 1995 (07.06.95) US (71) Applicant: SUPRATEK PHARMA INC. [CA/CA]; Suite 700, 275 St. Jacques, Montreal, Quebec H2Y 1M9 (CA). (71)(72) Applicant and Inventor: KABANOV, Alexander V. [RU/US]; 1304 South 126th Street, Omaha, NE 68144 (US). (72) Inventors: ALAKHOV, Valery, Yu; 48 David Kennedy, Baie- D'Urfe, Quebec H9X 3V4 (CA). SVESHNIKOV, Peter G.; #2, 6 Teply Stan Street, Moscow, 117133 (RU). SEVERIN, Eugenio S.; #65, 57/65 Novoslobodskaya Street, Moscow, 103055 (RU). (74) Agent: COLLINS, Bruce, M.; Mathews, Woodbridge & Collins, P.A., Suite 306, 100 Thanet Circle, Princeton, NJ 08540-3674 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: BIOLOGICAL AGENT COMPOSITIONS		
(57) Abstract Novel pharmaceutical compositions comprising a chemotherapeutic agent and a polyether block copolymer, and methods of treatment using the compositions.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

BIOLOGICAL AGENT COMPOSTIONS

This application is a continuation-in-part of U.S. Application No. 08/374,406, filed January 17, 1995, entitled "Improvements in Chemotherapeutic Compositions," which in turn is a continuation of U.S. Serial No. 07/957,998, filed
5 October 8, 1992.

The present invention relates, among other things, to (1) pharmaceutical compositions and methods for chemotherapeutic agents and (2) pharmaceutical compositions for biological agents, particularly those whose target cells or tissues are resistant to the biological agent.

10 A number of chemotherapeutic agents exhibit low solubility and stability in physiological fluids. Often, chemotherapeutic agents are poorly transported across cell membranes. Further, many of these agents are binding with plasma proteins as well as other nonspecific interactions in the blood stream before they can reach the target cancer.

15 A major roadblock to effective chemotherapeutic treatments is the resistance to biological agents that many neoplasms and microbial infections develop. The sensitivity of neoplastic cells to anti-cancer agents can decrease by a factor as high as 10^3 during the course of a chemotherapeutic regimen. When such resistance develops with respect to one agent, often the target cells
20 are found to also be resistant to a number of other biological agents to which they had not previously been exposed. See Goldstein et al., *Crit. Rev. Oncol. Hematol.*, 12: 243-253, 1992; *Goodman and Gilman's The Pharmacological Basis of Therapeutics*, 8th Ed., McGraw-Hill, New York, 1994. One mechanism by which such resistance develops is believed to involve the membrane pump

- 2 -



protein gp-170 (a glycoprotein P or P-gp protein). See Goldstein et al., *Crit. Rev. Oncol. Hematol.*, 12: 243-253, 1992.

It has now been discovered that these difficulties can be overcome by administering the biological agent in question in a formulation
 5 containing micelles of one or more block copolymers with the characteristics described below. Further, it has now been discovered that a certain subset of these block copolymers is particularly effective in delivering drugs and reversing resistance to a biological agent.

10 SUMMARY OF THE INVENTION

In one embodiment, the invention provides a pharmaceutical composition comprising:

- (a) a biological agent; and
- (b) a polyether block copolymer comprising an A-type
 15 linear polymeric segment joined at one end to a B-type linear polymeric segment, wherein the A-type segment is of relatively hydrophilic character, the repeating units of which contribute an average Hansch-Leo fragmental constant of about -0.4 or less and have molecular weight contributions between about 30 and about 500, wherein the B-type segment is of relatively hydrophobic character, the
 20 repeating units of which contribute an average Hansch-Leo fragmental constant of about -0.4 or more and have molecular weight contributions between about 30 and about 500, wherein at least about 80% of the linkages joining the repeating units for each of the polymeric segments comprise an ether linkage. In a preferred first embodiment, the polyether block copolymer is selected from the
 25 group consisting of polymers of formulas



wherein A and A' are A-type linear polymeric segments, B and B' are B-type linear polymeric segments, and R¹, R², R³ and R⁴ are either block copolymers of
 30 formulas (I), (II) or (III) or hydrogen and L is a linking group, with the proviso that no more than two of R¹, R², R³ or R⁴ are hydrogen.

- 3 -

In a preferred embodiment, the composition includes micelles of the block copolymer or forms micelles of the block copolymers during the course of administration or subsequent thereto. Preferably, at least about 0.1 % of the biological agent is incorporated in the micelles, more preferably, at least
5 about 1 % of the biological agent, yet more preferably, at least about 5 % of the biological agent.

In a preferred embodiment, the hydrophobe percentage of the copolymer of the composition is at least about 50% more preferably, at least about 60 %, yet more preferably 70 %.

10 In another preferred embodiment, the hydrophobe weight of the copolymer is at least about 900, more preferably, at least about 1700, yet more preferably at least about 2000, still more preferably at least about 2300.

In further preferred embodiments, the hydrophobe weight is at least about 2000 and the hydrophobe percentage is at least about 20 %, preferably 35%; or the hydrophobe weight is at least about 2300 and the
15 hydrophobe percentage is at least about 20 %, preferably 35%.

In yet another preferred embodiment, the the copolymer or copolymers of the composition display a critical micellar concentration ("CMC") of no more than about 0.5% wt/vol at 37°C in an isotonic aqueous solution,
20 preferably, no more than about 0.05% wt/vol, more preferably, no more than about 0.01% wt/vol, yet more preferably, no more than about 0.003% wt/vol.

Preferably, the copolymers of the composition conform to Formula (V), which is set forth in the text below. Particularly preferred among these copolymers are those having hydrophobe weights between about 1500
25 and about 2000, preferably between about 1710 and about 1780, and hydrophobe percentages between about 85% and about 95%, preferably between about 88% and about 92%. Also particularly preferred among these copolymers are those having hydrophobe weights between about 3000 and about 3500, preferably between about 3200 and about 3300, and hydrophobe
30 percentages between about 15% and about 25%, preferably between about 18% and about 22%. Additionally particularly preferred among these polymers are that having hydrophobe weights between about 3500 and about 4000, preferably

- 4 -

between about 3700 and about 3800, and hydrophobe percentages between about 25% and about 35%, preferably between about 28% and about 32%.

In a preferred embodiment, the composition comprises a chemotherapeutic agent.

5 In a second embodiment, the invention provides a pharmaceutical composition comprising a cytotoxic drug solubilized in polymeric micelles.

In another embodiment, the invention provides a method of treating a microbial infection or a tumor by administering a pharmaceutical
10 composition of the first or second embodiment.

In yet another embodiment, the invention provides a method a treating a diseased tissue that has resistance to a biological agent during the course of a treatment with this or another biological agent, the method comprising administering a composition comprising (a) a second biological
15 agent, which may be the same or different from the first biological agent, against which the tissue has resistance and (b) a micelle forming copolymer composition as described for the first or second embodiments of the invention.

In another embodiment, the invention provides a method of preventing or limiting tumor metastases by administering one of the anticancer
20 compositions of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

Figs. 1 shows the cytotoxicity, for SK-resistant cells or SK cells treated with daunorubicin in free or micellar form.

25 **Figs. 2** shows the kinetics of daunorubicin accumulation for SK-resistant cells or SK cells, respectively, treated with daunorubicin in free or micellar form.

Figs. 3A and 3B show the inhibition of MCF7-ADR^c cells incubated with various concentrations of doxorubicin and Pluronic L61.

30 **Fig. 3C** shows the cellular toxicity of Pluronic L61 against MCF7-ADR^c cells.

- 5 -

Fig. 4 shows the time course of clearance of [^3H]-Pluronic P85 from the blood and accumulation in the liver.

Fig. 5 shows a comparison of the blood concentration of [^3H]-Pluronic P85 administered *i.v.* or orally.

5 Fig. 6A shows liver concentrations of daunorubicin.

Fig. 6B shows blood concentrations of daunorubicinol over time post-injection.

Fig. 6C shows blood concentrations of daunorubicin over time post-injection.

10 Fig. 7 shows the change, during a course of treatment, in the volume of multidrug-resistant Sp2/0^{dnr} myeloma tumors in BALB/c mice. Volume was quantified as the mean tumor volume on a given day (V) over the mean volume on the first day of treatment (V₀).

15 Fig. 8 shows the change, during a course of treatment, in the volume of multidrug-resistant Sp2/0^{dnr} myeloma tumors in BALB/c mice.

Fig. 9 shows the inhibition of tumor metastasis in mice treated with doxorubicin with Pluronic P85 vs. mice treated with doxorubicin alone.

DEFINITIONS

The terms or phrases listed below shall have the following meaning:

- **biological agent** an agent that is useful for diagnosing or imaging or that can act on a cell, organ or organism, including but not limited to drugs (pharmaceuticals) to create a change in the functioning of the cell, organ or organism. Such agents can include but are not limited to nucleic acids, polynucleotides, antibacterial agents, antiviral agents, antifungal agents, anti-parasitic agents, tumoricidal or anti-cancer agents, proteins, toxins, enzymes, hormones, neurotransmitters, glycoproteins, immunoglobulins, immunomodulators, dyes, radiolabels, radio-opaque compounds, fluorescent compounds, polysaccharides, cell receptor binding molecules, anti-inflammatories, anti-glaucomic agents, mydriatic compounds and local anesthetics.
- 5 • **chemotherapeutic agent** a biological agent that inhibits the growth or decreases the survival of neoplastic or pathogenic microbial cells or inhibits the propagation (which includes without limitation replication, viral assembly or cellular infection) of a virus.
- **cytotoxic drug** a chemotherapeutic agent useful in treating cancer that is cytotoxic, particularly to rapidly dividing cells.
- **hydrophobe percentage** the percentage of the molecular weight of a block copolymer that is made up of B-type blocks. This value is also referred to as the "hydrophobe weight percentage."
- **hydrophobe weight** the molecular weight contribution of the B-type blocks of a block copolymer. This value is also referred to as the "hydrophobe molecular weight."
- **IC₅₀** the concentration at which 50% cytotoxicity is obtained. Cytotoxicity can be measured by the method of Alley et al., *Cancer Res.* 48: 589-601, 1988 or Scudiero et al., *Cancer Res.*, 48:4827, 1988. In particular, it can be measured based on the drug concentration at which a 50% reduction in the activity of mitochondrial enzymes is observed.

- 7 -

- **lipophilic moiety** a lipophilic substituent that is joined to a targeting moiety and that partitions into the lipophilic portion of copolymer micelles to associate the targeting moiety with such micelles.
- **microbe** a bacteria, mycoplasma, yeast or fungi, virus or parasite (such as a malaria parasite).
- **MDR** cells are multidrug resistant (MDR) if they are resistant to the activity of biological agents that act on cell lines that are parental to the MDR cells.
- **targeting moiety** a molecular structure that is recognized by a cellular, tissue, viral or substratum component such as cell-surface receptor or acceptor molecule.

5

DETAILED DESCRIPTION

It has been discovered that the effectiveness of the block copolymers of the invention in enhancing the potency of chemotherapeutic drugs and reversing MDR is highly dependent (a) on the hydrophobe percentage and

10 (b) on the hydrophobe weight. The effectiveness increases with either an increase in the percentage (a) or an increase in weight (b), or both. These hydrophobe percentage and hydrophobe weight increases also correlate with improved micelle formation properties wherein micelle formation for these copolymers occurs at lower concentrations. See, Hurter et al., *Macromolecules*

15 26: 5030, 1993; Hurter et al., *Macromolecules* 26: 5592, 1993; Alexandris et al., *Macromolecules* 27: 2414, 1994. While not wishing to be limited to a particular theory, it is believed that micelle formation serves as a surrogate for measuring the physical properties that lead to improved biological agent delivery properties. Again, not wishing to be limited to a particular theory, it is believed that it is not


20 micelles per se that lead to improved biological agent efficiency and reversion of multidrug resistance. If, using doxorubicin as a model biological agent, the ratio of (a) the IC_{50} (a measure of effective cytotoxicity concentration) for a copolymer-containing composition to (b) the IC_{50} for free doxorubicin is plotted against the concentration of copolymer, the plot is biphasic, with a rapid decrease in the

25 ratio seen as copolymer concentrations increase but remain under the CMC of the copolymer. Above the CMC, a rapid leveling off of the ratio is observed. See Figure 6B. Maximal enhancement of biological agent activity occurs above

- 8 -

the CMC, although enhancement activity is seen at concentrations, for the copolymer Pluronic L61, as low as 0.0001 % wt/vol, or less. The micellar form is also believed to be important to using the copolymers in drug delivery for other reasons, as will be discussed below.

- 5 The schematic below is helpful in understanding the relationship between the hydrophobe percentage and the hydrophobe weight of a copolymer and various aspects of the present invention. In the schematic, the weight of the hydrophobe (poly(oxypropylene)) and of the copolymer are shown directly under each identified copolymer. Adjacent to these values are the hydrophobe
10 percentage values for each copolymer.



- Pluronic F68 has been determined to have only a modest activity in enhancing the potency of biological agents. Pluronic L61, which has the same hydrophobe weight as Pluronic F68 but a much higher hydrophobe percentage, is generally the most effective of the block copolymers identified in the schematic. Pluronic
15 F108, which has the same hydrophobe percentage as Pluronic F68 but a much higher hydrophobe weight, is also an effective copolymer, though much less effective than Pluronic L61. Pluronic P85 has a greater hydrophobe weight and a greater hydrophobe percentage than Pluronic F68, but the difference in each value is less than it is for Pluronics F108 and L61, respectively. The effectiveness
20 of Pluronic P85 in enhancing the potency of biological agents is intermediate between the effectiveness of Pluronic F108 and of Pluronic L61. These differences in effectiveness are exemplified when various copolymers, at a

- 9 -

concentration above CMC, and doxorubicin are incubated *in vitro* with drug-resistant cells. The ratio of the IC₅₀ value for doxorubicin in the absence of copolymer to the ratio in the presence of copolymer is the "resistance reversion index." The resistance reversion index values for various copolymers are:

5	Doxorubicin formulation	IC ₅₀ , ng/ml	Resistance reversion index
	free drug	60,000	n.a.
	+ 5% (w/v) Pluronic F68	60,000	1
	0.01% (w/v) Pluronic F108	10,000	6
	0.01% (w/v) Pluronic P85	2,000	30
10	0.01% (w/v) Pluronic L61	60	1000

The importance of the micellar form in delivering biological agents is also revealed in *in vivo* experiments. In the micellar form, biological agents are located in the hydrophobic core of the micelles, thereby masked by the hydrophilic shell (composed of A-type segments) surrounding the micelles. This masking decreases interactions with liver, plasma proteins, other non-target tissues and other molecules that can bind or inactivate the agent or convert the agent to a toxic metabolite. For example, rapid metabolism of anthracycline antibiotics by the liver leads to the formation of cardiotoxic metabolites that are modified at the C13 position. See, Mushlin et al., *Br. J. Pharmacol.* 110: 975-982, 1993. Using doxorubicin as a model drug, the micellar form decreases liver uptake, decreases conversion to doxorubicinol, and decreases the rate at which the concentration of doxorubicin in the blood decreases. See Figures 4 and 5.

The effectiveness of copolymers in (a) forming micelles (where greater effectiveness is measured in reduced CMCs) and (b) favoring the partitioning of various biological agents to the micellar rather than the free form increases according to the same pattern (i.e., with increases in hydrophobe weight or hydrophobe percentage). Thus, the hierarchy of effectiveness is again L61 > P85 > F108 >> F68. The presence of micelles at low concentrations is believed to help assure, assuming that biological agent remains associated with the micelles, that the biological agent and the copolymer arrive together at a

- 10 -

target tissue. Partitioning coefficients that favor the micellar form help assure that the assumption that the biological agent remains associated with micelles will hold true. The micellar form of the biological agent is also believed to protect the biological agent from uptake by non-target tissues, which tissues may metabolize the biological agent into an ineffective or toxic metabolite, and non-specific adsorption to blood components, cellular components and the like.

The same pattern of copolymer effectiveness applies in the treatment of experimental tumors with anti-cancer drugs, as illustrated in the examples.

At high concentrations, block copolymers can be toxic to the liver, kidney or other cells of a subject. See, *BASF Corp., Pluronic Material Safety Data Sheet and Drug Master Files*. The toxicity of block copolymers increases with the hydrophobicity parameters of block copolymers according to the same pattern seen for increases in effectiveness in potentiating biological agents. Fortunately, the rate of increase in potency as these hydrophobicity parameters change is much greater than the increase in copolymer toxicity. For instance, as illustrated in Example 8, the LD₅₀ of L61 in BALB/c mice is 10-fold lower than the LD₅₀ of Pluronic F108. However, the difference in the optimal therapeutic dose is more than 100-fold improved for Pluronic L61 vs. Pluronic F108 (see Example 9B). Thus, the concentration range over which effectiveness in potentiating the activity of a biological agent can be maintained while avoiding toxicity due to copolymer is increased for Pluronic L61 vs. Pluronic F108.

Members of the glycoprotein P family of membrane proteins are believed to be responsible for the multidrug resistance of many of the tumors whose resistance can be reversed using the compositions of the invention. See, Goldstein et al., *Cancer Treatment Res.* 57: 101- 119, 1991. These proteins are believed to function as pumps that export the biological agent against which the tumors have become resistant. Members of the same protein family are believed to reside in the membranes of the endothelial cells lining blood vessels in the brain and to be responsible for the "blood-brain barrier" (BBB) that excludes effective amounts of many biological agents from the entering the brain. See, for example, Tatsuta et al., *J. Biol. Chem.* 267: 20383-20391. Compositions of the

- 11 -

present invention can be used to enhance drug permeability into the brain, as discussed in more detail in U.S. Application No. _____, filed concurrently herewith on June 7, 1995 and entitled "Compositions for Targeting Biological Agents," attorney Docket No. 313257-103A, the entire disclosure of which is
5 incorporated herein by reference. Further, members of this protein family are believed to be responsible for drug resistance in certain Candida, malaria and other microbial infections. Without wishing to be bound to a particular theory, it is believed that the compositions of the invention reverse efflux mechanisms mediated by members of the glycoprotein P family and other drug resistance
10 mechanisms.

The invention is described with reference to the fragmental constants developed by Hansch and Leo. See Hansch and Leo, *Substituent Constants for Correlation Analysis in Chemistry and Biology*, Wiley, New York, 1979; James, *Solubility and Related Properties*, Marcel Dekker, New York, 1986,
15 pp. 320-325. These constants were developed for use in estimating the contribution of a portion of a molecule to the tendency of the molecule to partition between the phases formed by octanol-water mixtures. These constants are generally referred to as Hansch-Leo fragmental partition constants (hereinafter "Hansch-Leo fragmental constants").

20 The compositions of the invention are generally intended to include either preformed micelles with a substantial portion of the biological agent dissolved therein, or copolymer compositions which form micelles with a substantial portion of the agent dissolved therein during the course of the administration of the biological agent to a patient or subsequent thereto. For the
25 embodiments of the invention wherein targeting moieties are associated with the micelles, the targeting moiety will either be pre-associated with micelles or will associate with micelles during the course of administration. Particularly preferred block copolymers are those that have low CMC values in isotonic solutions at physiological temperatures. Such block copolymers will maintain a micellar
30 delivery vehicle for biological agents even after substantial dilution into a physiological fluid such as a treatment subject's blood. Such low CMC values

- 12 -

allow for the use of reduced levels of block copolymers in the drug composition of the invention.


The entire disclosure of U.S. Application No. 08/374,406, filed January 17, 1995, is incorporated herein by reference.

5 The number of repeating units of the total hydrophilic (A-type) blocks or the total hydrophobic (B-type) blocks of a polyether copolymer are preferably be between about 4 and about 400. More preferably, the number of repeating units is between about 4 and about 200, still more preferably, between about 5 and about 80. The repeating units that comprise the blocks, for A-type
10 and B-type blocks, will generally have molecular weight between about 30 and about 500, preferably between about 30 and about 100, still more preferably between about 30 and about 60. Generally, in each of the A-type or B-type blocks, at least about 80% of the linkages between repeating units will be ether linkages, preferably, at least about 90% will be ether linkages, more preferably, at
15 least about 95% will be ether linkages. Ether linkages, for the purposes of this application, encompass glycosidic linkages (i.e., sugar linkages). However, in one aspect, simple ether linkages are preferred.


 Preferably, all of the repeating units that comprise A-type blocks have a Hansch-Leo fragmental constant of less than about -0.4, more preferably,
20 less than about -0.5, still more preferably, less than about -0.7. Preferably, all of the repeating units that comprise B-type blocks have a Hansch-Leo fragmental constant of about -0.30 or more, more preferably about -0.20 or more.

 Polymers according to the first embodiment of the invention are exemplified by the block copolymers having the formulas:


- 13 -




or,



or,



or,




in which x, y, z, i and j have values consistent with the parameters for polyether
 25 copolymers described above, and wherein for each R¹, R² pair, one shall be
 hydrogen and the other shall be a methyl group. Formulas (V) through (VII) are
 oversimplified in that, in practice, the orientation of the isopropylene radicals
 within the B block will be random. This random orientation is indicated in
 formula (VIII), which is more complete. Such poly(oxyethylene)-
 30 poly(oxypropylene) compounds have been described by Santon, *Am. Perfumer
 Cosmet.* 72(4):54-58 (1958); Schmolka, *Loc. cit.* 82(7):25-30 (1967); *Non-ionic
 Surfactants*, Schick, ed. (Dekker, NY, 1967), pp. 300-371. A number of such

- 14 -

compounds are commercially available under such generic trade names as "poloxamers," "pluronics" and "synperonics." Pluronic polymers within the B-A-B formula are often referred to as "reversed" pluronics, "pluronic R" or "meroxapol." The "polyoxamine" polymer of formula (VIII) is available from BASF (Wyandotte, MI) under the tradename Tetronic™. The order of the polyoxyethylene and polyoxypropylene blocks represented in formula (VIII) can be reversed, creating Tetronic R™, also available from BASF. See, Schmolka, *J. Am. Oil Soc.*, 59:110 (1979). Polyoxypropylene-polyoxyethylene block copolymers can also be designed with hydrophilic blocks comprising a random mix of ethylene oxide and propylene oxide repeating units. To maintain the hydrophilic character of the block, ethylene oxide will predominate. Similarly, the hydrophobic block can be a mixture of ethylene oxide and propylene oxide repeating units. Such block copolymers are available from BASF under the tradename Pluradot™.

A number of pluronics are designed to meet the following formula:



(IX)

Of course, the ordinarily skilled artisan will recognize that the values of m and n will usually represent a statistical average and that the number of repeating units of the first block of a given molecule will generally not be exactly the number of repeating units of the third block. The characteristics of a number of pluronics, described with reference to formula (IX), are as follows:

- 15 -

5	Copolymer	Hydrophobe weight	CMC (% w/v)	Hydrophobe percentage
	Pluronic L61	1750	0.0003	90
	Pluronic L64	1750	0.002	60
	Pluronic F68	1750	4-5	20
	Pluronic P85	2250	0.005 - 0.007	50
	Pluronic F127	4000	0.003 - 0.005	30
	Pluronic F108	3250	.003 - 0.007	20

These CMC values were determined by the surface tension method described in

10 Kabanov et al., *Macromolecules* 28: 2303-2314, 1995.

Additional specific poly(oxyethylene)-poly(oxypropylene) block copolymers relevant to the invention include:


	Pluronic	Hydrophobe Weight	Hydrophobe Percentage
15	L31	950	90%
	F35	950	50%
	L42	1200	80%
	L43	1200	70%
	L44	1200	60%
20	L62	1750	80%
	L63	1750	70%
	L64	1750	60%
	P65	1750	50%
	L72	2050	80%
25	P75	2050	50%
	L81	2250	90%
	P84	2250	60%
	F87	2250	30%
	F88	2250	20%
30	L92	2750	80%
	F98	2750	20%
	L101	3250	90%
	P103	3250	70%
	P104	3250	60%
35	P105	3250	50%
	F108	3250	20%
	L121	4000	90%
	L122	4000	80%

- 16 -

	L123	4000	70%
	F127	4000	30%
	10R5*	1000	50%
	10R8	1000	20%
5	12R3	1200	70%
	17R2	1700	80%
	17R1	1700	90%
	17R2	1700	80%
	17R4	1700	60%
10	17R8	1700	20%
	22R4	2200	60%
	25R1	2500	90%
	25R2	2500	80%
	25R4	2500	60%
15	25R5	2500	50%
	25R8	2500	50%
	31R1	3100	90%
	31R2	3100	80%
	31R4	3100	60%
20			

*All copolymers above this conform to formula (IX), this copolymer and those below conform to formula (VII).

The diamine-linked pluronic of formula (VIII) can also be a member of the family of diamine-linked polyoxyethylene-polyoxypropylene polymers of formula:



(X)

wherein the dashed lines represent symmetrical copies of the polyether
 35 extending off the second nitrogen, R* an alkylene of about 2 to about 6 carbons, a cycloalkylene of about 5 to about 8 carbons or phenylene, for R¹ and R², either (a) both are hydrogen or (b) one is hydrogen and the other is methyl, for R³ and R⁴ either (a) both are hydrogen or (b) one is hydrogen and the other is methyl, if both of R³ and R⁴ are hydrogen, then one R⁵ and R⁶ is hydrogen and the other

- 17 -

is methyl, and if one of R^3 and R^4 is methyl, then both of R^5 and R^6 are hydrogen. The $-NH_2-CH_2CH_2-NH_2-$ group of formula (VIII) and the $N-R^*-N$ group of formula (X) are examples of linking groups, L, of formula (IV).

Those of ordinary skill in the art will recognize, in light of the discussion herein, that even when the practice of the invention is confined for example, to poly(oxyethylene)-poly(oxypropylene) compounds, the above exemplary formulas are too confining. An important feature is that the average Hansch-Leo fragmental constant of the monomers in an A-type block be about 0.4 or less. Thus, the units making up the first block need not consist solely of ethylene oxide. Similarly, not all of the B-type block need consist solely of propylene oxide units. Instead, the blocks can incorporate monomers other than those defined in formulas (V)-(X), so long as the parameters of the first embodiment are maintained. Thus, in the simplest of examples, at least one of the monomers in block A might be substituted with a side chain group as previously described.

In another aspect, the invention relates to a drug composition made up of a block copolymer at least one of formulas (I) - (X), wherein the A-type and B-type blocks are substantially made up of repeating units of formula $-O-R^5$, where R^5 is:

- (1) $-(CH_2)_n-CH(R^6)-$, wherein n is zero or an integer from about 1 to about 5 and R^6 is hydrogen, cycloalkyl having about 3 to about 8 carbon atoms, alkyl having about 1 to about 6 carbon atoms, phenyl, alkylphenyl wherein the alkyl has about 1 to about 6 carbon atoms, hydroxy, hydroxyalkyl, wherein the alkyl has about 1 to about 6 carbon atoms, alkoxy having about 1 to about 6 carbon atoms, an alkyl carbonyl having about 2 to about 7 carbon atoms, alkoxycarbonyl, wherein the alkoxy has about 1 to about 6 carbon atoms, alkoxycarbonylalkyl, wherein the alkoxy and alkyl each independently has about 1 to about 6 carbon atoms, alkylcarboxyalkyl, wherein each alkyl independently has about 1 to about 6 carbon atoms, aminoalkyl wherein the alkyl has

- 18 -

- about 1 to about 6 carbon atoms, alkylamine or dialkylamino, wherein each alkyl independently has about 1 to about 6 carbon atoms, mono- or di-alkylaminoalkyl wherein each alkyl independently has about 1 to about 6 carbon atoms, chloro, 5 chloroalkyl wherein the alkyl has from about 1 to about 6 carbon atoms, fluoro, fluoroalkyl wherein the alkyl has from about 1 to about 6 carbon atoms, cyano or cyano alkyl wherein the alkyl has from about 1 to about 6 carbon atoms or carboxyl;
- 10 (2) a carbocyclic group having about 3 to about 8 ring carbon atoms, wherein the group can be for example, cycloalkyl or aromatic groups, and which can include alkyl having about 1 to about 6 carbon atoms, alkoxy having about 1 to about 6 carbon atoms, alkylamino having about 1 to about 6 carbon atoms, dialkylamino wherein each alkyl independently has about 1 to about 6 carbon atoms, amino, sulfonyl, hydroxy, 15 carboxyl, fluoro or chloro substitutions, or
- (3) a heterocyclic group, having about 3 to about 8 ring atoms, which can include heterocycloalkyl or heteroaromatic groups, which can include from about 1 to about 4 20 heteroatoms selected from the group consisting of oxygen, nitrogen, sulfur and mixtures thereto, and which can include alkyl having about 1 to about 6 carbon atoms, alkoxy having about 1 to about 6 carbon atoms, alkylamino having about 1 to about 6 carbon atoms, dialkylamino wherein each alkyl 25 independently has about 1 to about 6 carbon atoms, amino, sulfonyl, hydroxy, carboxyl, fluoro or chloro substitutions.

Preferably, n is an integer from about 1 to about 3. The carbocyclic or heterocyclic groups comprising R⁵ preferably have from about 4 to about 7 ring 30 atoms, more preferably about 5 about 6. Heterocycles preferably include from about 1 to about 2 heteroatoms, more preferably, the heterocycles have one

- 19 -

heteroatom. Preferably, the heterocycle is a carbohydrate or carbohydrate analog.

Those of ordinary skill will recognize that the monomers required to make these polymers are synthetically available. See, Vaughn et al.,
 5 *J. Am. Oil Chem. Soc.* 28: 294, 1951. In some cases, polymerization of the monomers will require the use of suitable protective groups, as will be recognized by those of ordinary skill in the art. Generally, the A and B-type blocks are at least about 80% comprised of -OR⁵- repeating units, more preferably at least about 90%, yet more preferably at least about 95%.

10 In another aspect, the invention relates to a drug composition made up of a block copolymer of one of formulas (I) - (X) wherein the A-type and B-type blocks consist essentially of repeating units of formula -O-R⁷-, wherein R⁷ is a C₁ to C₆ alkylene group.

The Hansch-Leo estimate of the octanol-water partitioning
 15 coefficient (P) for an organic molecule is calculated by the following formula:

$$\text{Log } P = \sum a_n f_n + \sum b_m F_m$$

where the f_n values are the fragmental constants for the different groups in the molecule, the a_n values are the number of any type of group in the molecule, the F_m values are factors for certain molecular features such as single bonds or
 20 double bonds, and the b_m values are the number of any such molecular feature. For instance, the Hansch-Leo fragmental constant for an ethylene oxide repeating unit (-CH₂CH₂O-) would be:

$$2f_C + 4f_H + f_O + (4-1)F_b = 2(0.20) + 4(0.23) + (-1.82) + 3(-0.12) = -0.86$$

The Hansch-Leo fragmental constant for a propylene oxide (-CH₂CH(CH₃)O-) repeating unit would be:

$$2f_C + f_{CH_3} + 3f_H + f_O + (4-1)F_b = 2(0.2) + 0.89 + 3(0.23) + (-1.82) + 3(-0.12) = -0.2$$

Those of ordinary skill in the art will recognize that the Hansch-Leo approach to estimating partition constants, in which approach the Hansch-Leo fragmental constants are applied, does not yield precisely the
 30 empirical partition constant. See Hansch and Leo, *Substituent Constants for Correlation Analysis in Chemistry and Biology*, Wiley, New York, 1979; James, *Solubility and Related Properties*, Marcel Dekker, New York, 1986, pp. 320-325.

- 20 -

However, the approach is precise enough to define the hydrophobicity features of the polymeric delivery vehicle.

The block copolymers utilized in the invention will preferably form micelles in isotonic aqueous solutions at a physiological temperature having
5 diameter from about 10 nm to about 100 nm. Micelles are supramolecular complexes of certain amphiphilic molecules that form in aqueous solutions due to microphase separation of the nonpolar portions of the amphiphiles. Micelles form when the concentration of the amphiphile reaches, for a given temperature, a CMC that is characteristic of the amphiphile. By varying the sizes of the
10 hydrophilic and hydrophobic segments of the block copolymers, the tendency of the copolymers to form micelles at physiological conditions, as well as the average size of the micelles formed at physiological conditions, can be varied. These tendencies can also be adjusted by blending copolymers with differing mixes of hydrophobic and hydrophilic blocks. The micelles have a dense core
15 formed by the water insoluble repeating units of the B blocks and lipophilic portions of a biological agent dissolved therein, and a hydrophilic shell formed by the A blocks and hydrophobic portions of the biological agent. The micelles have translational and rotational freedom in aqueous environment, and aqueous environments containing the micelles have low viscosity similar to water. Micelle
20 formation typically occurs at copolymer concentrations from about 0.0001 to 5% (w/v).

The small size of the micelles formed by block copolymers of the invention is believed to allow these micelles to penetrate in small capillaries and to be taken up by cells. The micelles also can incorporate large amounts of
25 appropriate biological agents. For instance, micelles formed by Pluronic L61 can incorporate at least 1 mg of doxorubicin per 2 mg of copolymer.

The effective retention of a drug within the micelles of the invention can be quantified in terms of the partitioning coefficient (P) determined using formula:

30
$$P = [\text{Agent}]_m / [\text{Agent}]_{aq}$$

where $[\text{Agent}]_{aq}$ is the concentration of biological agent in an aqueous environment outside of the micelles and $[\text{Agent}]_m$ is the concentration of agent in

- 21 -

the micelles. In some cases, P is facilely and accurately estimated based on the difference fluorescence properties of certain agents when in an aqueous vs. a more hydrophobic environment.

It will in some circumstances be desirable to incorporate, by
5 noncovalent association, targeting molecules. See, for example, Kabanov et al.,
J. Controlled Release, 22:141 (1992) and U.S. Application No. _____, filed
concurrently herewith on June 7, 1995 and entitled "Compositions for Targeting
Biological Agents," attorney Docket No. 313257-103A. The targeting molecules
that can be associated with the composition typically have a targeting moiety
10 having affinity for a cellular site and a lipophilic moiety. The targeting molecules
will spontaneously associate with the micelles and be "anchored" thereto through
the lipophilic moiety. These targeting molecules will typically comprise about
10% or less of the copolymers in a composition.

In the targeting molecule, the lipophilic moiety can be, among
15 other things, a lipid group such as a fatty acyl group. In a preferred
embodiment, the lipophilic moiety is a hydrocarbon having from about 3 to about
41 carbon atoms, more preferably a hydrocarbon having from about 5 to about
25 carbon atoms, yet more preferably, a hydrocarbon having from about 9 to
about 17 carbon atoms. Alternately, it can be a block copolymer or another
20 natural synthetic polymer. The targeting group of the targeting molecule will
frequently comprise an antibody, typically with specificity for a certain cell surface
antigen. It could also be, for instance, a hormone having a specific interaction
with a cell surface receptor, or a drug having a cell surface receptor. For
example, glycolipids could serve to target a polysaccharide receptor. A non-
25 limiting example of a targeting moiety is the anti- α_2 GP antibody to brain glial cells
(α_2 -glycoprotein) which is described by Chekhonin et al., *FEBS Lett.* 287: 149-
152, 1991.

For polyethylene oxide-polypropylene oxide copolymer, the
hydrophilic/hydrophobic properties, and micelle forming properties of a block
30 copolymer are related to the value of the ratio, n. The ratio, n, is defined as:

$$n = (|B|/|A|) \times (b/a) = (|B|/|A|) \times 1.32$$

- 22 -

where $|B|$ and $|A|$ are the number of repeating units in the hydrophobic and hydrophilic blocks of the copolymer, respectively, and b and a are the molecular weights for the respective repeating units. The value of n will typically be between about 0.2 and about 9.0, more preferably, between about 0.2 and about

5 1.5. Where mixtures of block copolymers are used, a value N will be used, which value will be the weighted average of n for each contributing copolymers, with the averaging based on the weight portions of the component copolymers. The value N can be used to estimate the micelle-forming properties of a mixture of copolymers. When copolymers other than polyethylene oxide-polypropylene
10 oxide copolymers are used, similar approaches can be developed to relate the hydrophobic/ hydrophilic properties of one member of the class of polymers to the properties of another member of the class.

In the second embodiment, the polymeric micelles are preferably formed of non-toxic, pharmaceutically acceptable polymers.

15 The pharmaceutical compositions of the invention can be administered by a number of routes, including without limitation orally, topically, rectally, vaginally, by pulmonary route, for instance, by use of an aerosol, or parenterally, including but not limited to intramuscularly, subcutaneously, intraperitoneally or intravenously. The compositions can be administered alone,
20 or can be combined with a pharmaceutically-acceptable carrier or excipient according to standard pharmaceutical practice. For the oral mode of administration, the compositions can be used in the form of tablets, capsules, lozenges, troches, powders, syrups, elixirs, aqueous solutions and suspensions, and the like. In the case of tablets, carriers that can be used include lactose,
25 sodium citrate and salts of phosphoric acid. Various disintegrants such as starch, and lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc, are commonly used in tablets. For oral administration in capsule form, useful diluents are lactose and high molecular weight polyethylene glycols. When aqueous suspensions are required for oral use, the compositions can be
30 combined with emulsifying and suspending agents. If desired, certain sweetening and/or flavoring agents can be added. For parenteral administration, sterile solutions of the conjugate are usually prepared, and the pHs of the

- 23 -

solutions are suitably adjusted and buffered. For intravenous use, the total concentration of solutes should be controlled to render the preparation isotonic. For ocular administration, ointments or droppable liquids may be delivered by ocular delivery systems known to the art such as applicators or eye droppers.

- 5 Such compositions can include mucomimetics such as hyaluronic acid, chondroitin sulfate, hydroxypropyl methylcellulose or poly(vinyl alcohol), preservatives such as sorbic acid, EDTA or benzylchonium chloride, and the usual quantities of diluents and/or carriers. For pulmonary administration, diluents and/or carriers will be selected to be appropriate to allow the formation
- 10 of an aerosol.

Suppository forms of the compositions of the invention are useful for vaginal, urethral and rectal administrations. Such suppositories will generally be constructed of a mixture of substances that is solid at room temperature but melts at body temperature. The substances commonly used to

15 create such vehicles include theobroma oil, glycerinated gelatin, hydrogenated vegetable oils, mixtures of polyethylene glycola of various molecular weights and fatty acid esters of polyethylene glycol. See, Remington's Pharmaceutical Sciences, 16th Ed., Mack Publishing, Easton, PA, 1980, pp. 1530-1533 for further discussion of suppository dosage forms. Analogous gels or creams can be


20 used for vaginal, urethral and rectal administrations.

The chemotherapeutic agents appropriate for use in this invention include, without limitation, vinca alkaloids such as vincristine and vinblastine, mitomycin-type antibiotics such as mitomycin C and N-methyl mitomycin C, bleomycin-type antibiotics such as bleomycin A₂, antifolates such

25 as methotrexate, aminopterin, and dideaza-tetrahydrofolic acid, colchicine, demecoline, etoposide, taxanes such as paclitaxel (Taxol[®]), anthracycline antibiotics and others. The anthracycline antibiotics exemplify drugs having delivery problems due to low stability, the development of drug resistance in the target tissue, or rapid metabolism. These antibiotics typically include a fused

30 tetracycline aglycone ring system joined at the 7-position to daunosamine. They include, for instance, the compounds represented by the formula:

- 24 -



5

wherein R^1 is hydroxy or methoxy; R^2 is hydrogen or hydroxy; and R^3 is ethyl,
 10 acetyl, hydroxyacetyl, or an ester of hydroxyacetyl. These tetracycline antibiotics,
 like many anti-neoplastic agents, are believed to act by intercalating between the
 planar aromatic ring structures of DNA, thereby interfering with DNA replication.
 See, Neidle and Waring, *Molecular Aspects of Anti-Cancer Drug Action*, Pitman
 Press, 1983. Neoplastic cells are generally particularly susceptible, since they
 15 are actively replicating and thus synthesizing replica copies of their DNA. Such
 tetracycline antibiotics include, without limitation, doxorubicin, daunorubicin,
 carminomycin, epirubicin, idarubicin, mithoxanthrone, 4-demethoxy-daunomycin,
 11-deoxydaunorubicin, 13-deoxydaunorubicin, adriamycin-14-benzoate,
 adriamycin-14-octanoate or adriamycin-14-naphthaleneacetate.

20 Preferred classes of biological agents (including
 chemotherapeutic agents) include anti-neoplastic agents, antibacterial agents,
 antiparasitic agents, antifungal agents, CNS agents, immunomodulators and
 cytokines, toxins and neuropeptides. Biological agents for which target cells
 tend to develop resistance mechanisms are also preferred. Particularly preferred
 25 biological agents include anthracyclines such as doxorubicin, daunorubicin,
 epirubicin, idarubicin, mithoxanthrone or carminomycin, vinca alkaloids,
 mitomycin-type antibiotics, bleomycin-type antibiotics, azole antifungals such as
 fluconazole, polyene antifungals such as amphotericin B, taxane-related
 antineoplastic agents such as paclitaxel and immunomodulators such as tumor
 30 necrosis factor alpha ($TNF\alpha$), interferons and cytokines.

Preferred biological agents (including chemotherapeutic agents)
 include without limitation additional antifungal agents such as amphotericin B,

- 25 -

- flucytosine, ketoconazole, miconazole, itraconazole, griseofulvin, clotrimazole, econazole, terconazole, butoconazole, ciclopirox olamine, haloprogin, tolnaftate, naftifine, nystatin, natamycin, undecylenic acid, benzoic acid, salicylic acid, propionic acid and caprylic acid. Such agents further include without limitation
- 5 antiviral agents such as zidovudine, acyclovir, ganciclovir, vidarabine, idoxuridine, trifluridine, foscarnet, amantadine, rimantadine and ribavirin. Such agents further include without limitation antibacterial agents such as penicillin-related compounds including β -lactam antibiotics, broad spectrum penicillins and penicillinase-resistant penicillins (such as methicillin, nafcillin, oxacillin, cloxacillin,
- 10 dicloxacillin, amoxicillin, ampicillin, ampicillin-sulbactam, azocillin, bacampicillin, carbenicillin, carbenicillin indanyl, cyclacillin, mezlocillin, penicillin G, penicillin V, piperacillin, ticarcillin, imipenem and aztreonam), cephalosporins (cephalosporins include first generation cephalosporins such as cephapirin, cefaxolin, cephalexin, cephradine and cefadroxil; second generation cephalosporins such as
- 15 cefamandole, cefoxitin, cefaclor, cefuroxime, cefuroxime axetil, cefonicid, cefotetan and ceforanide; third generation cephalosporins such as cefotaxime, ceftizoxime, ceftriaxone, cefoperazone and ceftazidime), tetracyclines (such as demeclocyclotetracycline, doxycycline, methacycline, minocycline and oxytetracycline), beta-lactamase inhibitors (such as clavulanic acid),
- 20 aminoglycosides (such as amikacin, gentamicin C, kanamycin A, neomycin B, netilmicin, streptomycin and tobramycin), chloramphenicol, erythromycin, clindamycin, spectinomycin, vancomycin, bacitracin, isoniazid, rifampin, ethambutol, aminosalicic acid, pyrazinamide, ethionamide, cycloserine, dapsone, sulfoxone sodium, clofazimine, sulfonamides (such as sulfanilamide,
- 25 sulfamethoxazole, sulfacetamide, sulfadiazine, and sulfisoxazole), trimethoprim-sulfamethoxazole, quinolones (such as nalidixic acid, cinoxacin, norfloxacin and ciprofloxacin), methenamine, nitrofurantoin and phenazopyridine. Such agents further include agents active against protozoal infections such as chloroquine, diloxanide furoate, emetine or dehydroemetine, 8-hydroxyquinolines,
- 30 metronidazole, quinacrine, melarsoprol, nifurtimox, pentamidine, sodium stibogluconate and suramin.

- 26 -

The dosage for a biological agent in a micellar composition will often be about that of the biological agent alone; dosages will be set by the prescribing medical professional considering many factors including the age, weight and condition of the patient and the pharmacokinetics of the agent. Often
5 the amount of a micellar form of an agent required for effective treatment may be less than the amount required using the free biological agent. For daunorubicin use in treating cancer, a typical dosage will be about 1 mg per kg of body weight. Vinblastine is typically administered at a dose of from 0.1 to 0.2 mg per kg of body weight.

10 Generally, the biological agents used in the invention are administered to an animal in an effective amount. The effect of the copolymer used in the composition on effectiveness must be considered in determining effective amount. Generally, an effective amount is an amount effective to either (1) reduce the symptoms of the disease sought to be treated or (2) induce a
15 pharmacological change relevant to treating the disease sought to be treated. For cancer, an effective amount includes an amount effective to: reduce the size of a tumor; slow the growth of a tumor; prevent or inhibit the formation of metastases; or increase the life expectancy of the affected animal.

In many cases, the metabolites of various biological agents
20 create or enhance the unwanted effects resulting from administering the agent. This is certainly the case for anthracycline-based drugs, where metabolites are believed to lead to cardiotoxicity. See, Mushlin et al., *Br. J. Pharmacol.* 110: 975-982, 1993. The copolymer compositions of the invention can decrease the rate of metabolism for biological agents, thereby reducing the potential for harmful
25 side effects.

Various antifungal agents successfully treat human fungal infections. However, the therapeutic dose is often a compromise between achieving effective drug levels and avoiding toxic side effects. In recent years, the emergence of drug resistance among intrinsically sensitive species such as
30 *Candida albicans* and the increasing incidence of intrinsically drug resistant species such as *Candida krusei* has prompted a search for newer antifungal agents.

- 27 -

Although fluconazole has a low incidence of side effects, the incidence of resistance is an increasing problem. Delivery vehicles that are effective in enhancing chemotherapeutic activity and reversing resistance to such agents is therefore desirable for this agent, as well as for other antimicrobial agents.

The invention is exemplified by the following non-limiting examples.

Example 1 - Fatty acyl conjugates

10 A solution of 50 μ l of 2 mg/ml of anti- α_2 GP antibody specific for the α_2 -glycoprotein of glial cells (Chekhomim et al., *FEBS Lett.* 287: 149-152, 1991) in 0.1 M borate buffer (pH 8.5) was mixed into 2 ml of 0.1 M AOT® {sodium bis(2-ethylhexyl)sulfosuccinate, available from Serva Chemicals, Germany} in octane. A reaction is initiated by adding a two-fold molar excess
15 (with respect to the polypeptide) of stearic acid chloride in 0.2 ml of 0.1 M AOT® in octane to the mixture. The stearic acid chloride was obtained from stearic acid (available from Reakhim, Russia) as described in Kabanov et al., *Molek Biologiya (Russian)*, 22: 473-484 (Engl. edn.: 382-391), 1988. The reaction was conducted overnight at 25°C. The product is precipitated three times with cold acetone,
20 dissolved in RPMI 1640 medium and sterilely filtered through a 0.22 μ m filter. (The polyclonal antibody used in this experiment also reacted with glial fibrillary acidic protein.)

Example 2 - Iodinated targeting moieties

25 Anti- α_2 GP antibody was labelled with ^{125} I using Bolton-Hunter reagent in the system of reversed micelles of AOT® in octane as described in Slepnev V.I. et al., *Bioconjugate Chem.*, 3, 273-274 (1992). Specific radioactivity of the ^{125} I-labelled protein ranges from 19 to 21 Ci/mol.

Wistar rats (80 g body weight, 8 animals/group) were injected
30 i.p. (0.1 ml/10 g body weight) with a composition made up of the ^{125} I-labelled anti- α_2 GP antibody (1 mCi/ml) dissolved in a mixture of 1.5% (w/v) copolymer Pluronic P85 and 2.5% (w/v) copolymer Pluronic L64 dissolved in RPMI 1640

- 28 -

medium. These copolymers, and all of the copolymers identified in the Examples, were obtained from Serva Chemicals, Germany. ¹²⁵I-labelled polypeptide dissolved in RPMI 1640 medium was administered at the same concentration. After three days the animals were killed, and tissue samples

5 taken for radioactivity assay to analyze tissue distribution as described by Chekhonin *et al.*, *FEBS Lett.*, 287 149-152 (1991). The distribution of radioactivity was quantitated by liquid scintillation counting. The experiments were repeated at least twice and the results were reproducible with less than 10% variation. The results, expressed as the ratio of brain radioactivity to the radioactivity in a given

10 tissue ($\pm$ S.D.), were as follows:

Organ	Relative Content of Label	
	Micelle	Control
Brain/heart	1.22 $\pm$ 0.91	0.11 $\pm$ 0.02
Brain/kidney	7.42 $\pm$ 0.56	0.05 $\pm$ 0.01
15 Brain/liver	9.02 $\pm$ 0.75	0.01 $\pm$ 0.00
Brain/lung	12.1 $\pm$ 0.92	0.04 $\pm$ 0.01
Brain/spleen	6.48 $\pm$ 0.39	0.01 $\pm$ 0.00
Brain/blood	8.85 $\pm$ 0.67	0.01 $\pm$ 0.00

20

Example 3A - Cytotoxicity against resistant cancer cells

Pluronic P85 was dissolved in RPMI 1640 medium (ICN Biomedicals Inc., Costa Mesa, CA) to a final concentration of 1%, and then the solution was sterilized by filtration to remove bacterial or fungal contamination.

25 This Pluronic P85 solution was used to make appropriate dilutions of sterile drug solutions for the cell culture experiments described below.

The cytotoxicity studies utilized the SKOV3 line of transformed cells (hereinafter "SK cells") and the SKVLB cell line derived therefrom (hereinafter "SK-resistant cells"). Both of these cell lines were provided by Dr. V. Ling,

- 29 -

University of Toronto. The SK-resistant cell line is a multi-drug resistant cell line derived from the SK cell line by long term cultivation in the presence of vinblastine.

Various dilutions of a number of anticancer agents were made
5 in RPMI medium or the Pluronic P85 solution described above. Cells were prepared for use in these experiments by plating an equal volume of a cell suspension (2000-3000 cells) into the wells of 96-well microtiter plates (Costar, Cambridge, MA) and cultured for 2 days. All cell culturing was done at 37°C and under a 5% CO₂ atmosphere. After this, 100 µl per plate of fresh medium (RPMI
10 1630 medium supplemented with 10% fetal calf serum) was added. The free anticancer agent or copolymer plus anticancer agent dilutions were applied to the wells in 100 µl volumes. The cells were exposed to the free or micellar form of a drug for two hours. After this incubation, the cells were washed three times with fresh medium. Then, the cells were cultured under fresh medium for an
15 additional four days.

The number of viable cells for each culture was determined by standard XTT analysis, which measures the activity of mitochondrial enzymes. See, Scudiero et al., *Cancer Res.*, 48:4827 (1988). 50 µl per well of sterile 1 mg/ml XTT (2,3-bis[2Methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-
20 carboxanilide inner salt, Sigma, St. Louis, MO) in PRMI-1640 containing 5 µl/ml of 1.54 mg/ml phenazine metasulphate (Sigma) in PBS was added to the cells. The cells were incubated for 16 hours, after which the absorbance of each well at 450 nm was determined. The SEM for any value determined (the mean of three determinations) was always within 10% of the value. IC₅₀ values (i.e., the
25 concentration at which 50% inhibition was achieved) were determined by extrapolating from graphs plotting the number of viable cells (i.e., the mitochondrial enzyme activity) versus the concentration of drug applied to the cells. The results for SK-resistant cells were as follows:

- 30 -

Agent:	Daunorubicin	Vinblastine	Mitomycin C	Methotrexate	Colchicine
	IC ₅₀ , (ng/ml)				
Free agent	6000	1200	2650	280	720
Agent in 1% P85	16	1.1	5.0	17.5	45.0

5

The raw data that generated the daunorubicin data in the above chart is shown graphically in Fig. 1, where drug concentration is plotted against percent inhibition of mitochondrial activity in SK-resistant cells for the free drug (line 1) and the micellar form of the drug (line 2). The corresponding data for SK cells is shown in Fig. 1 for the free and micellar forms of the daunorubicin (lines 3 and 4, respectively).

10

Example 3B - SK-resistance cells treated with various agents

The procedures described in Example 3A were used with SK-resistant cells. These cells were provided by Dr. V. Ling of the University of Toronto. The results were as follows:

15

Cytotoxic agent	IC ₅₀ , ng/ml	
	Free agent	Agent + 1% P85
Doxorubicin	60,000	3,000
Epirubicin	60,000	2,000
20 Vinblastine	1,200	1.1
Mitomycin C	800	10
Methotrexate	500	90
Colchicine	720	45

20

Example 3C - Kinetics of daunorubicin accumulation

25 The kinetics of daunorubicin accumulation in SK cells and SK-resistant cells was measured for cells treated with daunorubicin at 10 ng/ml by measuring the daunorubicin fluorescence accumulated in the cells (λ_{ex} = 471 nm, λ_{em} = 556 nm). The drug accumulation data for SK-resistant cells is displayed in

- 31 -

Fig. 2 (line 1: free drug; line 2: micellar form); the data for SK cells is also displayed in Fig. 2 (line 3: free drug; line 4: micellar form).

Example 3D - Doxorubicin titrations using different Pluronics

5 These experiments utilized the CH¹ C5 line of Chinese hamster ovarian carcinoma cells (provided by Dr. V. Ling or the Univ. of Toronto) and the methodology of Example 3A. For Pluronic L61 the concentration of copolymer applied to the cells was 0.01 % (w/v); for Pluronic P85 the concentration was 0.01 % (w/v); for Pluronic F108 the concentration was 0.01 % (w/v); for Pluronic
10 F68 the concentration was 5.0 % (w/v). The IC₅₀ values were:

Form of biological agent	IC ₅₀ (ng/ml)
Free doxorubicin	60,000
Pluronic L61	70
Pluronic P85	1000
15 Pluronic F108	2000
Pluronic F68	60,000

Example 3E - Copolymer titrations

The methodology of Example 3A was used except in two
20 details. The first difference was that doxorubicin-resistant MCF7 cells (MCF7-ADR^c cells, which described further in Example 21) were used in place of SK cells. Second, in addition to varying doxorubicin concentrations, the concentration of copolymer was also varied. The percent inhibition with change in doxorubicin concentration is shown in Figure 3A for cultures maintained in the
25 presence of varying concentrations of Pluronic L61. Line 1 is for free doxorubicin; line 2 is for doxorubicin in the presence of 0.61×10^{-6} M Pluronic L61; line 3 is for doxorubicin in the presence of 0.3×10^{-5} M Pluronic L61; line 4 is for doxorubicin in the presence of 0.16×10^{-4} M Pluronic L61; line 5 is for doxorubicin in the presence of 0.8×10^{-4} M Pluronic L61; line 6 is for doxorubicin
30 in the presence of 0.4×10^{-3} M Pluronic L61; and line 7 is for doxorubicin in the presence of 0.4×10^{-1} M Pluronic L61. In Figure 3B, these data are consolidated

- 32 -

such that the figure shows the IC_{50} value for doxorubicin applied to the cells in the presence of the indicated concentration of Pluronic L61.

Example 4- Copolymer cytotoxicity

5 MCF7-ADR^c cells (doxorubicin resistant cells described in Example 21) were incubated with Pluronic L61 at various concentrations and cytotoxicity was determined as described in Example 3A. The results are shown in Figure 3C.

10

Example 5A - Polymer biodistribution

Radioactive, tritium-containing derivatives of Pluronic P85 polymers were obtained from Kurchatov Institute of Atomic Energy, Moscow, Russia. 100 μ l per 20 g of body weight of a 1% w/v isotonic solution of the radioactive copolymer (2×10^7 cpm/20g body weight) was administered *i.v.* into 15 (a) BALB/c mice (from Kriukovo Veterinary Dept. of Russian Acad. Medical Sciences, Moscow, Russia) and (b) BALB/c mice into which 3×10^6 SP2/0^{dnr} murine myeloma cells (described in Example 9A) had been injected subcutaneously 6 weeks previously. The biodistribution of polymer at various 20 times post-injection of the radioactive copolymer was measured by sacrificing treated mice at the various timepoints, excising the tissues listed in the tables below, and quantifying the distribution of radioactivity by liquid scintillation counting. To prepare tissue samples for liquid scintillation counting, samples were placed in 1 ml of tissue solubilizer (available from Serva Chemicals, 25 Germany) and homogenized in the cold. The homogenates were incubated for 14 hours at room temperature, decolorized with 50 μ l of 30% hydrogen peroxide, and incubated overnight at room temperature.

For BALB/c mice lacking injected tumor cells, the results were:

- 33 -

Organ	Polymer content (% of initial dose per organ)		
	73 hours	92.5 hours	121 hours
Spleen	0.23	0.2	0.12
Liver	3.69	3.27	1.8

5

For BALB/c mice with injected tumor cells, the results were:

Organ	Polymer content (% of initial dose per organ)		
	73 hours	92.5 hours	121 hours
Spleen	0.35	0.47	0.36
Liver	3.71	3.35	3.35
Tumor	1.53	6.24	1.50

10

Additional observations derived from this set of experiments were (1) that degradation products of the polymers were not observed until 24 hours after polymer administration and (2) complete clearance of polymer from the mice occurred 250 to 300 hours after administration.

Example 6A - Blood concentrations of copolymer

100 μ l/20g body weight of the [^{3} H]-Pluronic P85 of Example 4 were administered to 6-week old BALB/c mice by *i.v.* injection. Figure 4 shows the amount of radioactivity found in the blood of the mice at various timepoints post-injection (dark line) and in the liver (dashed line).

Example 6B - Blood concentrations of copolymer

100 μ l/20g body weight of the [^{3} H]-Pluronic P85 of Example 4 were administered to 6-week old BALB/c mice by *i.v.* injection or orally. The amount of radioactivity found in the blood of the mice at various timepoints post injection is shown in Figure 5, where the first bar in each pair is for *i.v.* injected polymer, and the second bar is for orally administered polymer.

30

- 34 -

Example 7 - Daunorubicin and daunorubicinol pharmacokinetics

Daunorubicin metabolism was monitored by HPLC.

Daunorubicin (Sigma, St. Louis, MO) was injected *i.v.* into 7-week-old C57B1/6 mice at 10 mg/kg body weight using a saline vehicle or a saline vehicle
5 containing 1% w/v Pluronic P85. Injection volumes were 100 μ l/ 20g body weight. At various times after injection, the animals were sacrificed and blood and liver homogenate were extracted with chloroform: methanol 9:1. The extracts were dried and redissolved in aqueous 0.1% trifluoroacetic acid (TFA). The solubilized extract was injected onto a 4.6 x 150 mm C18, reversed-phase
10 HPLC column (15 micron Ultrasphere, Beckman, CA). The column was developed with a 0 to 40 acetonitrile gradient in 0.1% TFA and the peaks for daunorubicin and its metabolite daunorubicinol were identified and quantified. Figure 6A shows the concentration of daunorubicin in liver at 150 minutes post-injection, with bar A showing the level for free daunorubicin (μ g per 10 μ g of liver
15 tissue) and bar B showing the level for the copolymer formulation. Figure 6B shows the time course of daunorubicinol accumulation in the blood for mice administered free daunorubicin (line 1) or the copolymer form (line 2). Figure 6C shows the time course of daunorubicin accumulation in the blood for mice administered free daunorubicin (line 1) or the copolymer form (line 2).

20

Example 8 - Acute toxicity

The acute toxicity of Pluronic F108, P85 and L61 were studies in 5-week old BALB/c male mice. Each experimental group of mice included 6 mice. Various doses of isotonic Pluronic solutions were administered *i.p.* Animal
25 mortality was monitored daily for 14 days. The LD₅₀ and maximum tolerated dosage ("MTD", i.e., the maximal dose at which no animals among 6 equivalently treated animals died) were calculated by probit analysis. See, Chan and Hayes in *Principles and Methods of Toxicology*, Hayes, A.W., ed., Raven Press, New York, 1989, pp. 169-189. The results were as follows:

- 35 -

Pluronic	MTD, g/kg	LD ₅₀ , g/kg
Pluronic L61	0.1	0.8
Pluronic P85	0.2	0.8
Pluronic F108	5.0	9.0

5

Example 9A - Tumor treatment

A multidrug-resistant tumor cell line was created by multiple passaging the murine myeloma SP2/0 cell line in the presence of 100 ng/ml of daunorubicin. The resistant cell line, SP2/0^{dnr}, was found to 10-fold more resistant to epirubicin (IC₅₀ = 0.7 µg/ml for the parent cell line; IC₅₀ = 8.0 µg/ml for SP2/0^{dnr} line). When these resistant cells were used to form tumors in mice and, 50 days after the development of solid tumors, cells were recovered from the tumors, the recovered cells exhibited the same resistance.

The SP2/0^{dnr} cells (3 x 10⁶ cells) were injected subcutaneously into 6-week old BALB/c mice. On treatment day 0, which occurred 14 days after the injection of tumor cells, the mice were treated by *i.v.* injection 20 µl/20 of body weight of (1) saline, (2) an isotonic solution of epirubicin (5 mg/kg body weight) or (3) an isotonic solution of epirubicin dissolved in 1% Pluronic P85 (1 mg/kg body weight). The results, expressed as the change of the ratio of the mean volume of the tumors (V) to the mean volume of the tumors on treatment day 0 (V₀) over a 60 day course of treatment, are shown in Figure 7. Similar results were obtained with daunorubicin and with Pluronic L61 and F108.

Example 9B - Optimal therapeutic dose

The same procedure as described in Example 9A was used, except that the parental cell line (SP2/0, a non-resistant cell line) cell line was used and the copolymer used and the concentrations used were as follows:

- 36 -

copolymer	Concentrations (% w/v)		
	10%	5%	3%
Pluronic F108	10%	5%	3%
Pluronic P85	10%	1%	0.5%
Pluronic L61	1%	0.1%	0.01%

5

For Pluronic F108, the optimal antitumor efficacy was achieved using 10% copolymer. For Pluronic P85, the optimal antitumor efficacy was achieved using 1% copolymer. For Pluronic L61, the optimal antitumor efficacy was achieved using 0.1% copolymer. These values were designated the optimal therapeutic
 10 doses (OTDs) for the respective copolymers.

Example 9C - Time course using OTD amounts of copolymer

The same procedure as in Example 9B was substituting the OTD amount of each of Pluronic F108, Pluronic P85 and Pluronic L61 as the
 15 vehicle for epirubicin. The results are shown in Figure 8 (ordinate shows V/V_0).

Example 10

Pluronic F68 was diluted with RPMI 1640 medium to a final concentration of 2.0% at 4°C. The mixture was incubated for 30 minutes at 37°C
 20 and then sterilized by filtration through a 0.22 μ m filter. An equal volume of a solution of 200 μ g daunorubicin in RPMI 1640 medium added and this mixture was incubated for 30 minutes at 37°C.

Human ovarian carcinoma cells (CRL157 cells) were precultured in 1% solution of the Pluronic F68 in RPMI 1640 medium
 25 supplemented with 10% calf fetal serum. The daunorubicin/Pluronic solution was added and the mixture was incubated for 60 minutes at 37°C and the cells then washed three times with RPMI 1640 and cultured in RPMI 1640 supplemented with 10% calf fetal serum for 3 days. Cytotoxicity was measured, both for this preparation and a parallel preparation of free daunorubicin, using the method of
 30 Alley *et al.*, *Cancer Res.*, 48, 589-601 (1988). The results were as follows:

- 37 -

	conc.(ng/ml)	50000	10000	2000	400	80	16
	% Inhibition						
	Chemotherapeutic drug + Pluronic	100	100	92	24	6	2
5	Free drug	100	81	53	38	20	1

Following the same procedure, cytotoxicity was determined against human T-lymphoma (Jurkat) cells:

	conc.(ng/mL)	50000	10000	200	400	80	16	3.2
	% Inhibition							
	Chemotherapeutic drug + Pluronic	100	100	100	100	92	33	3
10	Free drug	100	100	100	84	51	44	22

15 Following the same procedure, cytotoxicity was determined against human small cell carcinoma of lung (H-69):

	conc.(ng/mL)	50000	10000	200	400	80	16	3.2
	% Inhibition							
	Chemotherapeutic drug + Pluronic	100	100	100	100	100	42	12
20	Free drug	100	100	100	91	69	42	20

Example 11

Block copolymers of poly(oxyethylene)-poly(oxypropylene) having the ratios of poly(oxypropylene) to poly(oxyethylene) indicated below were dispersed in RPMI 1640 medium at the concentrations indicated below. The mixtures were incubated for 40 minutes at 30°C. The average micelle diameter was measured by quasielastic light scattering. See Kabanov et al., *Macromolecules* 28: 2303-2314, 1995. The results were as follows:

- 38 -

copolymer	conc.	Avg. Diameter
F-68	1.0 %	726.0 nm
P-85	1.0 %	18.0 nm
L-64	1.0 %	20.4 nm
1:1.5 P-85:L-64	0.01%	17.0 nm
1:2.5 F-68:L-64	1.0 %	33.5 nm

Example 12

A 1:1.5 mixture of Pluronic P85 and Pluronic L64 having individual ratios (*n*) of (oxypropylene) to (oxyethylene) blocks of 1.00 and 1.50, respectively, and a combined value (*N*) of 1.30, was diluted with RPMI 1640 medium to a final concentration of 2.0% at 4°C. The mixture was incubated for 30 minutes at 37°C and then sterilized by filtration through a 0.22 μ m filter. An equal volume of a solution of 200 μ g daunorubicin in RPMI 1640 medium was added and this mixture was incubated for 30 minutes at 37°C.

Cytotoxicity to human ovarian cancer cells (CRL157 cells) was measured, both for this preparation and a parallel preparation of free daunorubicin as described in Example 3A. The results were as follows:

conc.(ng/mL)	50000	10000	2000	400	80	16	3.2
% Inhibition							
Chemotherapeutic drug + Pluronic	100	100	100	100	94	53	8
Free drug	100	100	81	50	29	10	2

The daunorubicin compositions were evaluated for cytotoxicity in (i) human T-lymphoma (Jurkat) cells and (ii) normal human mononuclear cells. The results were as follows:

- 39 -

conc.(ng/mL)	50000	10000	2000	400	80	16	3.2
Cell	% Inhibition						
Jur. ¹	100	100	100	100	100	74	28
Jur. ²	100	100	100	83	59	36	21
Norm. ¹	100	100	91	60	21	5	2
Norm. ²	100	100	80	58	23	18	1

¹Treated with chemotherapeutic drug + pluronic.²Treated with free (non-micellar) chemotherapeutic drug.10 Example 13

IC₅₀ values for (i) human T-lymphoma (Jurkat) cells and (ii) normal human mononuclear cells were determined for the daunorubicin composition of Example 12 and compared to those for free daunorubicin. Measurements were made at the indicated intervals of the drug contact with the

15 cells. The results were as follows:

time (hours)	0.25	0.50	0.75	1.0	2.0	4.0	8.0	12
Cell	IC ₅₀ (ng/mL)							
Jur. ¹	150	46	25	17	9.0	0.80	0.50	0.30
Jur. ²	120	68	35	25	19	16	3.0	5.2
Norm. ¹	3570	950	620	450	250	220	160	140
Norm. ²	4900	980	405	310	290	275	280	240

¹Treated with chemotherapeutic drug + pluronic.²Treated with free (non-micellar) chemotherapeutic drug.25 Example 14

The antineoplastic agent vinblastine was incorporated into the block copolymer mixture described in Example 12. The IC₅₀ of this preparation against SK cells was determined to be 0.121 μ g/mL; the IC₅₀ against SK-resistant cells was 0.0012 μ g/mL. The IC₅₀ values for free vinblastine were determined to be 0.095 μ g/mL against SK cells and 0.615 μ g/mL against SK-resistant cells.

30

- 40 -

Example 15

The antineoplastic agent mitomycin C was incorporated into the block copolymer mixture described in Example 12. The IC_{50} of this preparation against SK cells determined to be $0.265 \mu\text{g/mL}$; the IC_{50} against SK-resistant cells was $0.005 \mu\text{g/mL}$. The IC_{50} of free mitomycin C against SK cells was determined to be $0.320 \mu\text{g/mL}$; the IC_{50} against SK-resistant cells was $1.120 \mu\text{g/mL}$.

Example 16

The antineoplastic agent methotrexate was incorporated into the block copolymer mixture described in Example 12. The IC_{50} of this preparation against SK cells was determined to be $0.880 \mu\text{g/mL}$; the IC_{50} against SK-resistant cells was $0.0175 \mu\text{g/mL}$. The IC_{50} of free methotrexate against SK cells was determined to be $1.090 \mu\text{g/mL}$; and against SK-resistant cells was $1.340 \mu\text{g/mL}$.

Example 17

The antineoplastic agent colchicine was incorporated into the block copolymer mixture described in Example 12. The IC_{50} of this preparation against SK cells was determined to be $0.720 \mu\text{g/mL}$; the IC_{50} against SK-resistant cells was $0.045 \mu\text{g/mL}$. The IC_{50} of free colchicine against SK cells was determined to be $0.950 \mu\text{g/mL}$; and against SK-resistant cells was $7.450 \mu\text{g/mL}$.

Example 18

The antineoplastic agent daunorubicin was incorporated into the block copolymer mixture described in Example 12. The IC_{50} of this preparation against SK cells was determined to be $0.600 \mu\text{g/mL}$; the IC_{50} against SK-resistant cells was $0.0068 \mu\text{g/mL}$. The IC_{50} of free daunorubicin against SK cells was determined to be $0.620 \mu\text{g/mL}$; and against SK-resistant cells was $5.850 \mu\text{g/mL}$.

Example 19

To $30 \mu\text{L}$ of a 20 mg/mL solution of bovine serum albumin in phosphate buffered saline were added $30 \mu\text{L}$ of daunorubicin solution in the

- 41 -

block copolymer mixture described in Example 12. A second formulation was prepared in parallel fashion using free daunorubicin.

The preparations were incubated for 10 minutes at 25°C, and then analyzed by HPLC on a TSK-3000 SW gel-filtration column in PBS containing 0.3 M sodium chloride and 5% acetonitrile. Detection was performed at 280 nm and 470 nm. The portion of the drug bound with BSA determined as:

$$Db = Sb/Sf$$

in which:

10 Sb is the relative area of the 470 nm peak (corresponding to daunorubicin) which coincides in retention time for the 280 nm peak (corresponding to BSA); and

15 Sf is the relative area of the peak (or peaks) corresponding to daunorubicin which does not coincide in retention time of the BSA peak.

The results were as follows:

20	Composition	Db
	Chemotherapeutic drug + Pluronic	0.01
	Free drug	0.39

- 42 -

Example 20

Micellar daunorubicin obtained as described in Example 12 and free daunorubicin were incubated in the dark at 37°C and cytotoxicity to CRL157 cells (human ovarian carcinoma cells) was then determined in the manner described in Example 1.

The results were as follows:

time (hours):		2	4	12	24	48	96
IC ₅₀ , µg/mL							
10	Chemo-therapeutic + Pluronic	9.1	10.05	9.8	10.4	10.7	11.3
15	Free drug	400	475	1120	6300	10180	48900

Example 21

The daunorubicin composition of Example 12 and free daunorubicin were evaluated against daunorubicin-sensitive human breast cancer cells (MCF7 cells) and two drug resistant cell lines: daunorubicin/verapamil-resistant (MCF-7AU) not expressing P-170, and daunorubicin-resistant, verapamil-sensitive (MCF7-ADR[®]), expressing P-170. These cells were provided by the Cell Bank of the Moscow Research Center of Molecular Diagnostics, Moscow, Russia.. The results were as follows:

- 43 -

conc.(ng/mL)		50000	10000	2000	400	80	16
% Inhibition							
5	MCF-7 ¹	100	100	84	65	42	12
	MCF-7AU ¹	100	100	100	96	69	39
	MCF7-ADR ^{c1}	100	100	100	89	73	45
	MCF-7 ²	100	100	91	69	43	15
	MCF-7AU	100	89	65	37	9	3
10	MCF7-ADR ^{c2}	100	86	62	39	7	2

¹Treated with chemotherapeutic drug + pluronic.²Treated with free (non-micellar) chemotherapeutic drug.

Free daunorubicin exhibits higher IC₅₀'s (is less toxic) against both resistant lines. Daunorubicin incorporated in the block copolymers exhibited lower IC₅₀'s (more toxic) against both resistant lines.

Example 22

Groups (6 animals/dose point) of C57B1/6 7-week-old female mice were inoculated i.p. with free or micellar daunorubicin obtained as described in Example 12. The mice were observed for 14 days. Drug concentrations were adjusted so that a maximum volume of 0.5 mL was injected in each mouse.

The MTD was defined as the maximum dose which leads to no daunorubicin-deaths (any higher dose leads to the daunorubicin-related death of at least 1 animal per group). The experiment was repeated twice. The results were reproducible with less than 10% variation.

The MTD of free and micellar daunorubicin was determined to be 2.0 and 1.0 µg/kg body weight, respectively.

- 44 -

Example 23

Daunorubicin causes bone marrow repression and leads to reversible leukopenia, *i.e.*, a decrease in the number of white blood cells (leukocyte count) during drug administration. Bone marrow suppression, as well as anticancer effects of daunorubicin, are believed to be due to DNA-intercollating activity, whereas the most harmful side effect of anthracyclines, cardiotoxicity, are believed to result mainly from metabolites (which have low anticancer activity and do not produce significant effects on bone marrow). Therefore, the leukocyte count during *in vivo* administration of an MTD of daunorubicin allows for the assessment of the ratio between specific (DNA-intercalation) activity of the drug and non-specific toxicity.

Groups (6 animals/group) of C57B1/6 7-week-old female mice were inoculated i.p. with free or micellar daunorubicin obtained as described in Example 12. Drug formulations comprising the MTD for the respective formulation were adjusted so that a maximum volume of 0.5 mL was injected in each mouse. Blood samples were collected and viable leukocytes were counted as described in Michisch *et al. Proc. Natl. Acad. Sci. USA* 88, 547-551 (1991). The number of WBC after administration of 0.1 mL PBS was used as the control. This value was 15-16 million cells/ml. The experiment was repeated twice. The results were reproducible with less than 10% variation.

The results obtained were as follows:

Days	0	3	7	10	14
WBS, % of control					
Chemo-therapeutic + Pluronic	100	20	46.6	86.6	100
Free drug	100	40	60	93.8	100

Example 24

The effects of free and micellar daunorubicin obtained as described in Example 12 on leukocyte count were determined three days after administration as described in Example 23.

- 45 -

The results obtained were as follows:

Dose of daunorubicin % of MTD		25	50	75	100
WBS, % of control					
5	Chemotherapeutic drug + Pluronic	85	73	45	21
	Free drug	78	61	36	39

The data shown in Examples 22 through 24 indicate that
 10 solubilization of daunorubicin in the block copolymer micelles does not markedly
 affect the drug's overall toxicity (MTD of 2 mg/kg and 1 mg/kg for free and
 micellar drug, respectively), whereas solubilization increases bone marrow
 suppression indicating an increase in anticancer potency.

15 Example 25

Anti-neoplastic activity was determined by evaluating the
 cytotoxic activity of plasma of mammals inoculated with the test compositions
 (see de Valeriola *et al.*, *Cancer Chemother. Pharmacol.* 29, 133-140, 1991).

Groups (6 animals/group) of C57Bl/6 7-week-old female mice
 20 were inoculated i.v. (via the tail vein) with free or micellar daunorubicin obtained
 as described in Example 12. Drug formulations comprising the MTD for the
 respective formulation were adjusted so that a maximum volume of 0.1 mL was
 injected in each mouse. The experiment was repeated twice. The results were
 reproducible with less than 10% variation.

25 To obtain plasma samples, blood (10 μ l) collected from the tail
 artery one hour after drug administration, diluted 1:10 with sterile RPMI 1640
 medium, and centrifuged at 400 g for 15 minutes. The supernatants obtained
 were diluted as shown in the table with plasma analogously obtained from mice
 not inoculated with the drug (the plasma of mice not inoculated with the drug
 30 does not produce any significant cytotoxic effect on H-69 cells) and mixed with
 an equal volume of a suspension of H-69 cells in RPMI 1640 medium
 supplemented with 10% fetal calf serum. The cells were incubated for two hours

- 46 -

at 37°C and 5% CO₂, and then washed three times with RPMI 1640. The pretreated cells were incubated in RPMI 1640 supplemented with 10% fetal calf serum at 37°C and 5% CO₂ for three days, after which cytotoxicity determined as described in Example 10.

5 The results obtained were as follows:

Dilution of Plasma	1:20	1:200	1:2000	1:20000
Inhibition, %				
Chemotherapeutic drug + Pluronic	100	58	8	0
10 Free drug	42	5	0	0

Thus, the serum from mice treated with the micellar formulation had much greater cytotoxic potency.

15 Example 26

The procedure of Example 25 was repeated utilizing SK cells and SK-resistant cells. The results were as follows:

a) When a dose equaling the MTD of a formulation of daunorubicin was introduced into the mice and the cytotoxicity of the resulting plasma measured, the results were:

Plasma Dilution	1:20	1:200	1:2000
Inhibition, %			
SK-resistant ¹	82	61	18
SK-resistant ²	0	0	0
25 SK ¹	11	0	0
SK ²	9	0	0

¹Treated with chemotherapeutic drug + pluronic.

²Treated with free (non-micellar) chemotherapeutic drug.

b) When 10 mg/kg daunorubicin was introduced into each mouse the resulting plasma cytotoxicities were:

- 47 -

Plasma Dilution	1:20	1:200	1:2000
Inhibition, %			
SK-resistant ¹	100	94	69
SK-resistant ²	8	0	0
5 SK ¹	62	31	0
SK ²	22	6	0

¹Treated with chemotherapeutic drug + pluronic.²Treated with free (non-micellar) chemotherapeutic drug.10 **Example 27 - Fluconazole treatment of candida**Culture media

The medium used for susceptibility testing was high resolution (HR) medium. This medium is optimal for fluconazole testing and is prepared in two parts as follows. Part A comprises 0.2M phosphate buffer pH 7.5 made

- 15 using Na₂HPO₄ sterilized by autoclaving. Part B comprises 2.93g of HR powder (Unipath) and 0.2g of sodium bicarbonate dissolved in 100ml of deionized water, this is then sterilized by filtration and stored at 4°C. Prior to use, equal quantities of Part A and B are mixed.

Organisms

- 20 The organisms used in this study were fresh clinical isolates of *Candida* species or control organisms used for routine susceptibility testing of antifungal agents. The isolates were selected to cover a range of fluconazole sensitivities ranging from fluconazole sensitive (minimum inhibitory concentration (MIC) of 0.2 µg/ml) to fluconazole resistant (MIC of 100 µg/ml). All isolates were
- 25 subcultured onto Sabourauds agar and incubated for 48 hrs. prior to susceptibility testing.

Preparation of yeast suspensions

- Suspensions of the yeast were prepared by touching five individual colonies and suspending them in sterile water to yield a slightly cloudy
- 30 suspension. This suspension was then diluted 1:100 in HR medium to yield a suspension containing 2x10⁴ organism/ml.

- 48 -

Polymer/fluconazole complexes

Polymers were obtained from Serva Chemicals, Germany. Complexes of polymer with fluconazole were prepared. Prior to use, each solution was filtered through a $0.4\mu\text{m}$ filter (Sartorius) to ensure sterility.

5 Preparation of fluconazole/polymer dilutions

Five polyether block copolymers were evaluated initially to test the efficacy of fluconazole in the presence of polymer and in the absence. Dilutions of fluconazole/polymer solutions were made with solutions containing the same copolymer. By such dilution, stock solutions containing $1250\mu\text{g/ml}$ fluconazole were made. This stock solutions were further diluted in polymer to give a range of fluconazole concentrations from $1250 - 2.5\mu\text{g/ml}$. As a control, fluconazole was dissolved in water to give a range of concentrations from $1250 - 2.5\mu\text{g/ml}$.

Minimum Inhibitory Concentration (MIC) tests

15 For MIC testing $8\mu\text{l}$ of each dilution of fluconazole in polymer or in water was added to the wells of a sterile microtitre plate. Two sets of controls were also established containing either $8\mu\text{l}$ of water or $8\mu\text{l}$ of fluconazole free polymer. The former served as a drug free control; the latter assessed any effect of the polymer on the yeast. HR medium was then added to each well to make
20 the volume up to $100\mu\text{l}$. Finally, $100\mu\text{l}$ of each yeast suspension was added to the respective row of fluconazole dilutions. Each yeast suspension was inoculated onto blood agar and Sabourauds agar to ensure purity and as a check on inoculum size. Each yeast was therefore tested against fluconazole at final concentrations of $50\mu\text{l/ml} - 0.1\mu\text{g/ml}$ in five different polymers or in water.
25 The final polymer concentration in each well was 4% and the final yeast concentration was 1×10^4 organisms/ml. The plates were mixed gently and then incubated for 48 hrs. at 37°C in a moist atmosphere. Plates were examined visually after 24 hrs. At 48 hrs., the plates were shaken on a rotary mixer for five minutes to suspend the yeast cells in the medium and then the OD490 was
30 measured using sterile culture medium as a blank.

- 49 -

Interpretation of MIC

For each organism, growth was assessed in the drug free positive control well, this was then compared with the polymer control well, if the OD490 of the polymer containing well was <90% of the OD490 of the control well, then the polymer was assumed to have an intrinsic inhibitory effect on the organism and the MIC result was invalid. If the OD490 of the polymer control was >90% of the positive control, then no inhibitory effect was assumed to occur and the rest of the results were interpreted.

For each polymer and organism, the MIC was taken as the lowest fluconazole concentration which reduced growth (OD490) by $\geq 50\%$ of the OD490 of the positive control. The following breakpoints were used for isolates in this study <6.2 $\mu\text{g/ml}$ - Sensitive, 6.2 and 12.5 $\mu\text{g/ml}$ - Intermediate sensitivity and >12.5 $\mu\text{g/ml}$ - Resistant. The results were as follows:

Organism	Species	Minimum inhibitory concentration (MIC), $\mu\text{g/ml}$			
		Fluconazole	F68 + Flucon.	F108 + Flucon.	P85 + Flucon.
1936	<i>C. albicans</i>	>50	50	50	25
1904	<i>C. albicans</i>	50	50	50	25
1905	<i>C. kruzei</i>	>50	>50	>50	>50
1803	<i>C. albicans</i>	1.5	0.8	0.3	0.4
1961	<i>C. glabrata</i>	3.1	1.5	0.4	0.8
Y01-09	<i>C. albicans</i>	0.4	0.2	0.1	0.2
2026	<i>C. albicans</i>	6.2	6.2	0.8	1.5
1996	<i>C. glabrata</i>	6.2	3.1	1.5	1.5

Example 28 - The activity of $\text{TNF}\alpha$

The cytotoxic activity of $\text{TNF}\alpha$ with respect to resistant SK-cells was determined using the XTT assay as described in Example 3A. $\text{TNF}\alpha$ was added to cells for 24 hours at various concentrations: 1) free $\text{TNF}\alpha$; b) $\text{TNF}\alpha$ in 0.1% Pluronic P85 and c) $\text{TNF}\alpha$ in 0.01% Pluronic L61. After 24 hour incubation

- 50 -

with $\text{TNF}\alpha$ the cells were washed with RPMI-1640 and analyzed by XTT assay. All experimental points were triplicates. Data were mean $\pm$ SEM. The results were as follows:

5	TNF α concentration (nM)	Cytotoxicity, %		
		TNF α	+Pluronic P85	+Pluronic L61
	0.01	0	7	40
	0.05	4	20	65
	0.2	5	42	90
10	1.0	4	80	100
	5	16	98	100
	20	19	100	100
	50	30	100	100
	100	50	100	100
15	200	90	100	100

Example 29 - Treatment of experimental glioma tumor.

The antibodies (Ab) to GFAP and α 2-glycoprotein were modified with stearic acid residues as described in example 1. They were also covalently linked to Pluronic P85 as described by Kabanov et al. J. Controlled Release, 22:141 (1992).

The therapeutic efficacy of doxorubicin in treatment of glioma was explored. C6 glioma cells were inoculated intracerebrally in groups (n = 25) of male Sprague-Dawley rats (280 - 300 g) obtained from Kriukovo Department of Nursery of Russian Academy of Sciences. 10, 15, 20, and 25 days after inoculation, (a) 10 mg/kg of free doxorubicin, (b) doxorubicin in 1% Pluronic P85, (c) doxorubicin in 10% Pluronic P85 containing 0.1 mg/ml of Ab modified with stearic acid chloride and (d) doxorubicin in 10% Pluronic P85 containing 0.1 mg/ml of Ab linked to Pluronic P85 were administered i.p. (volume 1 ml/300 g body weight). Controls will be given injections i.p. with an equal volume of saline. Clinical observations were performed daily. Animals were weighted

- 51 -

weekly in the first 2 months and monthly thereafter. Vital signs will be verified to ensure that the animal was dead and necropsy was initiated within 5 min. after the animal died. Data on survival was analyzed to grade the drug effect on tumor incidence and latency. The data were presented as a ratio of median survival times in the treated group (T) and control (C). For necropsy all major organs were saved and fixed in their entirety. The tail (used in the study for animal identification during in-life phase) was saved in formalin with the animal tissues. All brains were removed and trimmed at three different positions. Three sections of the spinal cord were collected at the cervical, thoracic and lumbar level. Trimmed specimen was placed in Tissue Tek cassettes and processed in a tissue processor. Tissue sections were cut at a thickness of 4-6 mm using a microtome and stained with haematoxylin-eosine. Histopathological examinations of brains assessed: (i) the total number of tumors in animals; (ii) the number of tumor bearing animals; and (iii) the histopathological classification and grading of tumors. The results of the experiment are as follows:

Animal group	Median survival, days	Trial/control x 100%
Control	11.2	-
Free doxorubicin	10.5	-
Micellar doxorubicin	25.3	226
Micellar doxorubicin + strearoylated antibodies	41.0	366
Micellar doxorubicin + conjugated antibodies	24.5	218

The histopathological examinations also revealed that 1) free doxorubicin caused no effect on tumor size and number compared to control; 2) all 3 micellar formulations caused significant decrease in tumor size and number; 3) the most pronounced effect was observed in the case of micellar doxorubicin + strearoylated antibodies, in this case tumors were practically not observed.

- 52 -

Example 30 - Inhibition of Metastatic Processes

Lewis lung carcinoma H59 cells (2×10^5) were injected subcutaneously into 6-week old male C57B1/6 mice. Mice were sacrificed by CO₂ over-exposure on day 21 and the number and size of metastatic tumors was determined as described by

5 Wilmanns, C; Fan, D.; O'Brian, C.A. et al. (1992) *Int. J. Cancer Inst.* 52, 98-104. The cancer cells injection resulted in formation of a solid tumor in the site of injection, and metastatic tumors in lung and liver. Tumor samples from 2 mice were harvested and adapted to culture as described by Dong, Z.; Radinsky, R.; Fan, D.; Tsan, R.; Bucana, C.D.; Wilmanns, C. and Fidler, I.J. (1994) *Int. J.*

10 *Cancer Inst.* 86, 913-920. The *in vitro* sensitivity of the cell samples to free and micellar doxorubicin (in 0.01% Pluronic L61) was determined using XTT assay as described in Example 3A. The results are presented in Fig. 9. The metastatic cells in lung were characterized by resistance to free doxorubicin. This resistance was reversed in the case of micellar drug. The metastatic cells in liver

15 were sensitive to free drug, their IC₅₀ approximated the IC₅₀ observed in parental H59 cell line. Still the cytotoxicity of the micellar drug with respect to liver metastatic cells was considerably higher than the cytotoxicity of the free drug.

20 Example 31

A composition suitable for parental administration was prepared by dissolving 400 mg of Pluronic P-85 and 600 mg of Pluronic L-64 in 50 mL of RPMI 1640 at 4°C. The mixture was incubated for 30 minutes at 37°C and then sterilized by filtration through a 0.22 μ m filter. The filtered solution was mixed

25 with a solution of 10 mg of sterile lyophilized daunorubicin powder dissolved in 50 mL of RPMI and incubated for 30 minutes at 37°C.

The composition can be stored in the dark at room temperature for 7 days without loss of activity or can be lyophilized and stored for at least 1 year in the dark at room temperature.

- 53 -

Example 32

A further composition suitable for parenteral administration was prepared by dissolving 400 mg of Pluronic P-85 and 600 mg of Pluronic L-64 in 50 mL of PBS at 4°C. The mixture was incubated for 30 minutes at 37°C and
5 then was sterilized by filtration through a 0.22 μ m filter. The filtered solution was mixed with a solution of 1 mg of sterile lyophilized daunorubicin powder and 5 mg of glucose dissolved in 50 mL of PBS and the mixture was incubated for 30 minutes at 37°C.

The composition can be stored in the dark at room temperature
10 for 7 days without loss of activity or can be lyophilized and stored for at least 1 year in the dark at room temperature.

Example 33

A further composition suitable for parenteral administration
15 prepared by dissolving 100 mg of sodium ascorbate in 100 ml of a 9% aqueous solution of sodium chloride. To one-half of this solution were added at 4°C 400 mg of Pluronic P-85 and 600 mg of Pluronic L-64. The mixture was incubated for 30 minutes at 37°C and then sterilized by filtration through a 0.22 μ m filter. Separately 10 mg of sterile lyophilized daunorubicin powder and 50 mg of
20 glucose were dissolved in the remaining sodium ascorbate-sodium chloride solution and the two solutions were mixed and incubated for 30 minutes at 37°C.

This composition can be stored for 30 days in the dark at room temperature without loss of activity or can be lyophilized and stored for at least 1 year in the dark at room temperature.

25

Example 34

A further composition suitable for parenteral administration is prepared by dissolving 100 mg of sodium ascorbate in 100 ml of a 9% aqueous solution of sodium chloride. To this solution are added at 4°C 10 mg of Pluronic
30 L-61. The mixture is incubated for 30 minutes at 37°C and then sterilized by filtration through a 0.22 μ m filter. This solution is packaged together with a container of 10 mg doxorubicin.

- 54 -

What is claimed:

1. A composition comprising:
 - (a) an anticancer chemotherapeutic agent; and
 - (b) a polyether block copolymer comprising an A-type
- 5 linear polymeric segment, the repeating units of which contribute an average Hansch-Leo fragmental constant of about -0.4 or less and have molecular weights between about 30 and about 500, joined at one end to a B-type linear
- polymeric segment, the repeating units of which contribute an average Hansch-Leo fragmental constant of about -0.4 or more and have molecular
- 10 weights between about 30 and about 500, and wherein at least about 80% of the linkages joining the repeating units for each of the polymeric segments comprise an ether linkage.
2. The composition of claim 1, wherein the composition: (i)
- 15 comprises micelles comprising the polyether block copolymer, or (ii) forms micelles comprising the polyether block copolymer during the course of administration to an animal or subsequent thereto.
3. The composition of claim 2, wherein at least about
- 20 0.1 % of the biological agent is in the micelles prior to or during the course of administration.
4. The composition of claim 3, wherein at least about 1% of the biological agent is in the micelles prior to or during the course of
- 25 administration.
5. The composition of claim 1 wherein the polyether block copolymer is selected from the group of block copolymers consisting of
- A-B-A', A-B, B-A-B', and L(R¹)(R²)(R³)(R⁴)
- 30 (I) (II) (III) (IV)
- wherein A and A' are A-type linear polymeric segments, wherein B and B' are B-type linear polymeric segments, and wherein R¹, R², R³ and R⁴ are (1) block

20

10. The composition of claim 9 wherein each A-type polymeric segment and B-type polymeric segment consists essentially of repeating units of formula $-O-R^5$, wherein R^5 is

(1) $-(CH_2)_n-CH(R^6)-$, wherein n is zero or an integer from about 1 to about 5 and R^6 is hydrogen, cycloalkyl having about 3 to about 8 carbon atoms, alkyl having about 1 to about 6 carbon atoms, phenyl, alkylphenyl wherein the alkyl has about 1 to about 6 carbon atoms, hydroxy, hydroxyalkyl, wherein the alkyl has about 1 to about 6 carbon atoms, alkoxy having about 1 to about 6 carbon atoms, an alkyl carbonyl having about 2 to about 7 carbon atoms, alkoxycarbonyl, wherein the alkoxy has

- 56 -

- about 1 to about 6 carbon atoms, alkoxycarbonylalkyl, wherein the alkoxy and alkyl each independently has about 1 to about 6 carbon atoms, alkylcarboxyalkyl, wherein each alkyl independently has about 1 to about 6 carbon atoms, aminoalkyl wherein the alkyl has about 1 to about 6 carbon atoms, alkylamine or dialkylamino, wherein each alkyl independently has about 1 to about 6 carbon atoms, mono- or di-alkylaminoalkyl wherein each alkyl independently has about 1 to about 6 carbon atoms, chloro, chloroalkyl wherein the alkyl has from about 1 to about 6 carbon atoms, fluoro, fluoroalkyl wherein the alkyl has from about 1 to about 6 carbon atoms, cyano or cyano alkyl wherein the alkyl has from about 1 to about 6 carbon atoms or carboxyl;
- (2) a carbocyclic group having about 3 to about 8 ring carbon atoms, wherein the group can be for example, cycloalkyl or aromatic groups, and which can include alkyl having about 1 to about 6 carbon atoms, alkoxy having about 1 to about 6 carbon atoms, alkylamino having about 1 to about 6 carbon atoms, dialkylamino wherein each alkyl independently has about 1 to about 6 carbon atoms, amino, sulfonyl, hydroxy, carboxyl, fluoro or chloro substituents, or
- (3) a heterocyclic group, having about 3 to about 8 ring atoms, which can include heterocycloalkyl or heteroaromatic groups, which can include from about 1 to about 4 heteroatoms selected from the group consisting of oxygen, nitrogen, sulfur and mixtures thereto, and which can include alkyl having about 1 to about 6 carbon atoms, alkoxy having about 1 to about 6 carbon atoms, alkylamino having about 1 to about 6 carbon atoms, dialkylamino wherein each alkyl

- 57 -

independently has about 1 to about 6 carbon atoms, amino, sulfonyl, hydroxy, carboxyl, fluoro or chloro substituents.

5 11. The composition of claim 1, wherein the hydrophobe weight percentage of the polyether block copolymer is at least about 50%

10 12. The composition of claim 11, wherein the hydrophobe weight percentage of the polyether block copolymer is at least about 60%.

13. The composition of claim 1, wherein the hydrophobe molecular weight of the polyether block copolymer is at least about 900.

15 14. The composition of claim 13, wherein the hydrophobe molecular weight of the polyether block copolymer is at least about 1700.

20 15. The composition of claim 14, wherein the hydrophobe molecular weight of the polyether block copolymer is at least about 2000 and the hydrophobe weight percentage is at least about 20%.

16. The composition of claim 15, wherein the hydrophobe molecular weight of the polyether block copolymer is at least about 2300 and the hydrophobe weight percentage is at least about 20%.

25 17. The composition of claim 1, wherein the composition comprises one or more of the polyether block copolymers and the polyether block copolymers comprising the composition have a critical micellar concentration ("CMC") of about 0.5% wt/vol or less at 37°C in an isotonic aqueous solution.


30

- 58 -

18. The composition of claim 17, wherein the polyether block copolymers comprising the composition have a CMC of about 0.05% wt/vol or less at 37°C in an isotonic aqueous solution.

5 19. The composition of claim 18, wherein the polyether block copolymers comprising the composition have a CMC of about 0.01% wt/vol or less at 37°C in an isotonic aqueous solution.

20. The composition of claim 1, wherein the polyether block
10 copolymer has the formula:



15 wherein n and m are integers of from about 4 to about 400.

21. The composition of claim 20, wherein the hydrophobe weight percentage of the polyether block copolymer is at least about 50%

20 22. The composition of claim 21, wherein the hydrophobe weight percentage of the polyether block copolymer is at least about 60%.

23. The composition of claim 20, wherein the hydrophobe molecular weight of the polyether block copolymer is at least about 900.

25

24. The composition of claim 23, wherein the hydrophobe molecular weight of the polyether block copolymer is at least about 1700.

25 25. The composition of claim 20, wherein the hydrophobe molecular weight of the polyether block copolymer is at least about 2000 and the
30 hydrophobe weight percentage is at least about 20%.

59 -

26. The composition of claim 25, wherein the hydrophobe molecular weight of the polyether block copolymer is at least about 2300 and the hydrophobe weight percentage is at least about 20%.
- 5 27. The composition of claim 20, wherein the composition comprises one or more of the polyether block copolymers and the polyether block copolymers comprising the composition have a critical micellar concentration ("CMC") of about 0.5% wt/vol or less at 37°C in an isotonic aqueous solution.
- 10 28. The composition of claim 27, wherein the polyether block copolymers comprising the composition have a CMC of about 0.05% wt/vol or less at 37°C in an isotonic aqueous solution.
- 15 29. The composition of claim 28, wherein the polyether block copolymers comprising the composition have a CMC of about 0.01% wt/vol or less at 37°C in an isotonic aqueous solution.
- 20 30. The composition of claim 20, wherein the hydrophobe molecular weight of the polyether block copolymer is between about 1500 and about 2000 and the hydrophobe weight percentage is between about 85% and about 95%.
- 25 31. The composition of claim 20, wherein the hydrophobe molecular weight of the polyether block copolymer is between about 3000 and about 3500 and the hydrophobe weight percentage is between about 15% and about 25%.
- 30 32. The composition of claim 20, wherein the hydrophobe molecular weight of the polyether block copolymer is between about 3500 and about 4000 and the hydrophobe weight percentage is between about 25% and about 35%.

- 60 -

33. The composition of claim 1, wherein the anticancer
chemotherapeutic agent is a vinca alkaloid, mitomycin-type antibiotic, bleomycin-
type antibiotic, antifolate, colchicine, demecoline, etoposide, taxane or
5 anthracycline antibiotic.

34. The composition of claim 33, wherein the anticancer
chemotherapeutic agent is doxorubicin, daunorubicin, carminomycin, epirubicin,
idarubicin, mithoxanthrone, 4-demethoxy-daunomycin, 11-deoxydaunorubicin,
10 13-deoxydaunorubicin, adriamycin-14-benzoate, adriamycin-14-octanoate or
adriamycin-14-naphthaleneacetate.

35. A composition comprising:

(a) an biological agent; and

15 (b) a polyether block copolymer comprising an A-type
linear polymeric segment, the repeating units of which contribute an average
Hansch-Leo fragmental constant of about -0.4 or less and have molecular weight
contributions between about 30 and about 500, joined at one end to a B-type
linear polymeric segment, the repeating units of which contribute an average
20 Hansch-Leo fragmental constant of about -0.4 or more and have molecular
weight contributions between about 30 and about 500, and wherein at least
about 80% of the linkages joining the repeating units for each of the polymeric
segments comprise an ether linkage, wherein:

(i) the polyether block copolymer has a hydrophobe
25 weight percentage of at least about 50%;

(ii) the polyether block copolymer has a hydrophobe
molecular weight of at least about 900; or

(iii) the composition comprises one or more of said
polyether block copolymers and the polyether
30 block copolymers comprising the composition
have a CMC of about 0.5% wt/vol or less at 37°C
in an isotonic aqueous solution.

- 61 -

36. The composition of claim 35 wherein the polyether block copolymer is selected from the group of block copolymers consisting of

A-B-A', A-B, B-A-B', and L(R¹)(R²)(R³)(R⁴)

(I) (II) (III) (IV)

5 wherein A and A' are A-type linear polymeric segments, wherein B and B' are B-type linear polymeric segments, and wherein R¹, R², R³ and R⁴ are (1) block copolymers of formulas (I), (II) or (III) or (2) hydrogen and L is a linking group, with the proviso that no more than two of R¹, R², R³ or R⁴ can be hydrogen, and mixtures thereof.

10

37. The composition of claim 36 wherein the repeating units for each A-type polymeric segment and B-type polymeric segment have molecular weight between about 30 and about 100.

15

38. The composition of claim 37 wherein at least about 90% of the linkages joining the repeating units for each A-type polymeric segment and B-type polymeric segment comprise ether linkages.

39. The composition of claim 38 wherein all of the repeating
20 units that comprise the B-type polymeric segment have a Hansch-Leo fragmental constants of about -.30 or more.

40. The composition of claim 39 wherein all of the repeating
25 units that comprise the A-type polymeric segment have a Hansch-Leo fragmental constants of about -0.5 or less.

41. The composition of claim 40 wherein each A-type polymeric segment and B-type polymeric segment consists essentially of repeating units of formula -O-R⁵, wherein R⁵ is

30

(1) -(CH₂)_n-CH(R⁶)-, wherein n is zero or an integer from about 1 to about 5 and R⁶ is hydrogen, cycloalkyl having about 3 to about 8 carbon atoms, alkyl having about 1 to

- 62 -

- about 6 carbon atoms, phenyl, alkylphenyl wherein the alkyl has about 1 to about 6 carbon atoms, hydroxy, hydroxyalkyl, wherein the alkyl has about 1 to about 6 carbon atoms, alkoxy having about 1 to about 6 carbon atoms, an alkyl carbonyl having about 2 to about 7 carbon atoms, alkoxycarbonyl, wherein the alkoxy has about 1 to about 6 carbon atoms, alkoxycarbonylalkyl, wherein the alkoxy and alkyl each independently has about 1 to about 6 carbon atoms, alkylcarboxyalkyl, wherein each alkyl independently has about 1 to about 6 carbon atoms, aminoalkyl wherein the alkyl has about 1 to about 6 carbon atoms, alkylamine or dialkylamino, wherein each alkyl independently has about 1 to about 6 carbon atoms, mono- or di-alkylaminoalkyl wherein each alkyl independently has about 1 to about 6 carbon atoms, chloro, chloroalkyl wherein the alkyl has from about 1 to about 6 carbon atoms, fluoro, fluoroalkyl wherein the alkyl has from about 1 to about 6 carbon atoms, cyano or cyano alkyl wherein the alkyl has from about 1 to about 6 carbon atoms or carboxyl;
- (2) a carbocyclic group having about 3 to about 8 ring carbon atoms, wherein the group can be for example, cycloalkyl or aromatic groups, and which can include alkyl having about 1 to about 6 carbon atoms, alkoxy having about 1 to about 6 carbon atoms, alkylamino having about 1 to about 6 carbon atoms, dialkylamino wherein each alkyl independently has about 1 to about 6 carbon atoms, amino, sulfonyl, hydroxy, carboxyl, fluoro or chloro substituents, or
- (3) a heterocyclic group, having about 3 to about 8 ring atoms, which can include heterocycloalkyl or heteroaromatic groups, which can include from about 1

63 -

to about 4 heteroatoms selected from the group consisting of oxygen, nitrogen, sulfur and mixtures thereto, and which can include alkyl having about 1 to about 6 carbon atoms, alkoxy having about 1 to about 6 carbon atoms, alkylamino having about 1 to about 6 carbon atoms, dialkylamino wherein each alkyl independently has about 1 to about 6 carbon atoms, amino, sulfonyl, hydroxy, carboxyl, fluoro or chloro substituents.

5

10

42. The composition of claim 35, wherein the hydrophobe weight percentage of the polyether block copolymer is at least about 60%.

43. The composition of claim 35, wherein the hydrophobe molecular weight of the polyether block copolymer is at least about 1700.

44. The composition of claim 35, wherein the hydrophobe molecular weight of the polyether block copolymer is at least about 2000 and the hydrophobe weight percentage is at least about 20%.

20

45. The composition of claim 44, wherein the hydrophobe molecular weight of the polyether block copolymer is at least about 2300 and the hydrophobe weight percentage is at least about 20%.

25


46. The composition of claim 35, wherein the polyether block copolymers comprising the composition have a CMC of about 0.05% wt/vol or less at 37°C in an isotonic aqueous solution.

47. The composition of claim 46, wherein the polyether block copolymers comprising the composition have a CMC of about 0.01% wt/vol or less at 37°C in an isotonic aqueous solution.

30

- 64 -

48. The composition of claim 35, wherein the polyether block copolymer has the formula:



wherein n and m are integers between about 4 and about 400.

49. The composition of claim 48, wherein the hydrophobe
10 weight percentage of the polyether block copolymer is at least about 60%.

50. The composition of claim 48, wherein the hydrophobe molecular weight of the polyether block copolymer is at least about 1700.

15 51. The composition of claim 49, wherein the hydrophobe molecular weight of the polyether block copolymer is at least about 2000 and the hydrophobe weight percentage is at least about 20%.

52. The composition of claim 51, wherein the hydrophobe
20 molecular weight of the polyether block copolymer is at least about 2300 and the hydrophobe weight percentage is at least about 20%.

53. The composition of claim 48, wherein the polyether block copolymers comprising the composition have a CMC of about 0.05% wt/vol or
25 less at 37°C in an isotonic aqueous solution.

54. The composition of claim 53, wherein the polyether block copolymers comprising the composition have a CMC of about 0.01% wt/vol or
less at 37°C in an isotonic aqueous solution.

30

55. The composition of claim 35, wherein the biological agent is an amphotericin B, flucytosine, triazole, imidazole, β -lactam antibiotic,

- 65 -

cephalosporins, tetracycline, beta-lactamase inhibitors, aminoglycosides, chloramphenicol, erythromycin, clindamycin, spectinomycin, vancomycin, bacitracin, isoniazid, rifampin, ethambutol, aminosalicylic acid, pyrazinamide, ethionamide, cycloserine, dapsone, sulfoxone sodium, clofazimine, sulfonamides, 5 trimethoprim-sulfamethoxazole, quinolones, methenamine, nitrofurantoin or phenazopyridine.

56. A method of treating a subject, wherein the subject has resistance to a biological agent, the method comprising administering a 10 composition comprising the biological agent and a micelle forming copolymer composition having a CMC of no more than about 0.5% wt/vol at 37°C in an isotonic aqueous solution.

57. The method of claim 56, wherein the copolymer 15 composition has a CMC of no more than about 0.05% wt/vol at 37°C in an isotonic aqueous solution.

58. The method of claim 57, wherein the copolymer 20 composition has a CMC of no more than about 0.01% wt/vol at 37°C in an isotonic aqueous solution.

59. A method of treating a subject, wherein the subject has resistance to a biological agent, the method comprising administering a composition comprising the biological agent and a copolymer comprising an 25 A-type linear polymeric segment, the repeating units of which contribute an average Hansch-Leo fragmental constant of about -0.4 or less, joined at one end to a B-type linear polymeric segment, the repeating units of which contribute an average Hansch-Leo fragmental constant of about -0.4 or more.

30 60. The method of claim 59, wherein the hydrophobe weight percentage of the polyether block copolymer of the administered composition is at least about 50%

- 66 -

61. The composition of claim 60, wherein the hydrophobe weight percentage of the polyether block copolymer of the administered composition is at least about 60%.

5 62. The composition of claim 59, wherein the hydrophobe molecular weight of the polyether block copolymer of the administered composition is at least about 900.

63. The composition of claim 62, wherein the hydrophobe
10 molecular weight of the polyether block copolymer of the administered composition is at least about 1700.

64. The composition of claim 63, wherein the hydrophobe molecular weight of the polyether block copolymer of the administered
15 composition is at least about 2000 and the hydrophobe weight percentage is at least about 20%.

65. The composition of claim 64, wherein the hydrophobe molecular weight of the polyether block copolymer of the administered
20 composition is at least about 2300 and the hydrophobe weight percentage is at least about 20%.

66. A method of treating a cancer comprising administering to an animal in need of treatment an anti-cancer effective amount of the
25 composition of claim 1

67. A method of treating a microbial infection comprising administering to an animal in need of treatment an antimicrobial effective amount of the composition of claim 1.

30

- 67 -

68. A method of inhibiting or preventing tumor metastases comprising administering an tumor metastasis inhibiting or preventing amount of the composition of claim 1.

5 69. A method of treating cancer comprising administering an anticancer effective amount of the composition of claim 1.



70. The method of treating cancer of claim 69, wherein the cancer is a leukemia, breast cancer, ovarian cancer, pancreatic cancer, lung
10 cancer, myeloma, melanoma, glioma or astrocytoma.

71. The method of treating cancer of claim 70, wherein the cancer is a a Hodgkin's lymphoma, non-hodgkin's lymphoma, acute lymphocytic lymphoma, acute myelocytic lymphoma, acute non-lymphatic leukemia, Kaposi's
15 sarcoma, small-cell lung cancer, non-small cell lung cancer or glial astrocytoma.

72. A composition to overcome multidrug resistance in cancer cells to cytotoxic drugs, comprising an effective amount of at least one cytotoxic drug from the group consisting of anthracycline and drugs related to
20 multidrug resistance solubilized in non-toxic, pharmaceutically acceptable polymeric micelles.

73. A method to overcome multidrug resistance in cancer cells to cytotoxic drug in the treatment of cancer with the cytotoxic drugs,
25 comprising administering to a patient in chemotherapy an effective amount of at least one cytotoxic drug solubilized in non-toxic, pharmaceutically acceptable polymeric micelles.

1/8



SUBSTITUTE SHEET (RULE 26)

2/8

FIG. 3A





FIG. 3B



3/8

FIG. 3C






FIG. 4



4/8

FIG. 5



5/8

FIG. 6A





FIG. 6B



6/8

FIG. 6C






FIG. 7



7/8

FIG. 8



SUBSTITUTE SHEET (RULE 26)

8/8

FIG. 9

